- Published on
UVEITIS AND RETINITIS, or CHORIORETINITIS
ESSENTIALS DESCRIPTION
Any inflammation of the choroid, ciliary body, and iris, which are located between the outer (sclera and cornea) and inner (retina) coats of the eye, is referred to as uveitis.
• There are several types of uveitis:
- Anterior (limited to the anterior chamber and iris)
as ciliary body involvement or iritis, as well as
as iridocyclitis in this instance.
In the interim (should the inflammatory process emerge in the
pars planitis, or peripheral retina
In the event that the inflammatory process develops in the
vitreous and choroid, whether or not they are involved
of the retina
Panuveitis (should the infection disregard any
anatomical limits inside the eye
• Despite not being a component of the uvea, the retina frequently becomes
either directly (retinitis) or indirectly (chorioretinitis) involved in inflammatory eye conditions. Neurotropic organisms like Toxoplasma gondii and herpes viruses are particularly prone to affecting the retina.
• Acute, recurring, and chronic uveitis can be distinguished based on the temporal pattern of ocular involvement; this differentiation is often useful in establishing a precise diagnosis.
The study of epidemiology
The prevalence
• It is estimated that there are 15 to 50 instances of uveitis per 100,000 people each year.
• Up to 10% of all blindness cases in the US are caused by infectious and noninfectious uveitis.
• The majority of uveitis is anterior uveitis, which includes iritis and iridocyclitis.
• In one-third to one-fifth of cases, idiopathic uveitis, no etiologic diagnosis can be made.
• Based on population-based studies, the distribution of uveitis by anatomic site is as follows:
- Front: 73%
Posterior: 22%
Panuveitis: 5%; Intermediate: 1%
• The choroid frequently serves as a trap for blood-borne infections because of its enormous blood flow and architecture. Common choroidal/retinal lesions that also invade the vitreous (endogenous fungal)
Approximately 1% to 2% of patients with invasive Candida species or candidemia develop endophthalmitis. infections.
The frequency
According to estimates, there are roughly 115 instances of infected and noninfectious uveitis for every 100,000 people in the United States. Prevalence figures vary from 75 to 700 instances per 100,000 people worldwide, with poorer nations providing the highest estimates. The length of the study has an impact on prevalence estimates since the longer a group is investigated, the more likely it is that cases of recurrent uveitis will become active.
RISK ELEMENTS
• In patients with AIDS or HIV-unrelated immunosuppression, a drop in the CD4+ T-lymphocyte count below 50 cells/μL is a substantial risk factor for CMV retinitis.
• AIDS is also a risk factor for progressive outer retinal necrosis (PORN), a typical manifestation of necrotizing retinitis linked to VZV.
Genetics
• Despite having a modest positive predictive value, HLA-typing has been widely utilized to diagnose patients with noninfectious uveitis. Therefore, HLA-typing should only be used to validate a particular clinical suspicion.
• When seronegative spondyloarthropathies are present, anterior uveitis is linked to HLA-B27.
• 85–95% of people with Birdshot's chorioretinopathy, a prevalent condition that causes posterior uveitis, have HLA-A29.
• HLA-B51 is around nine times more common in people with Adamantiades-Behcet's illness than in the general population, while HLA-DR2 and HLA-DR15 have been linked to intermediate uveitis.
OVERALL PREVENTION
To the extent that the related illness or infection can be avoided, so can ocular inflammation. For instance, preventing pregnant women with weakened immune systems from consuming raw or undercooked meat and potentially soil-contaminated fruits and vegetables can reduce the incidence of vertically transmitted ocular toxoplasmosis.
Pathophysiology
• Uveitis is typically brought on by an immunological response.
This could be an autoimmune reaction to several uveitogenic ocular antigens (such as Retinal S-Antigen) or a host's reaction to invasive pathogens.
• Autoimmune conditions such rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, and seronegative spondyloarthropathies are often diagnosed in conjunction with uveitis. In certain situations, immune system components that interact with loci in the retina, ciliary body, iris epithelium, or retinal pigmented epithelium may cause uveitis.
Ethiology
Bacterial infections are among the infectious causes of uveitis.
Non-standard mycobacteria
Bejel
Brucellosis
Leptospirosis with cat-scratch disease (Bartonella henselae)
Leprosy
Whipple's disease, tuberculosis, syphilis, nocardiosis, and Lyme illness
– Spreading
CMV, or cytomegalovirus
EBV, or Epstein-Barr virus
HSV, or herpes simplex virus
VZV, or varicella zoster virus
Mumps, human T cell leukemia virus, and human immunodeficiency virus (HIV)
Rubella
Rubeola
The West Nile virus
Fungi-induced Aspergillosis
Coccidiomycosis, Cryptococcosis, Candidiasis, and Blastomycosis
Presumed Ocular Histoplasmosis Syndrome (POHS): Histoplasmosis
Boydii pseudoallescheria
The parasitic disease sporotrichosis
Acanthamoeba (causes intraocular inflammation and keratitis)
Pneumocystis carinii, Onchocerciasis, Cysticercosis, and Toxocariasis
In western countries, toxoplasmosis is the most frequent cause of posterior uveitis.
• One prominent cause of chorioretinitis is CMV retinitis, which is becoming less common in the HAART era and is typically linked to advanced HIV infection. Up to 30% of AIDS patients would acquire CMV retinitis prior to the availability of HAART.
• In healthy hosts, toxoplasmosis is a surprisingly frequent cause of uveitis. It is thought to be a congenitally acquired infection reactivating. Serology-supported typical chorioretinal lesions are used to make the diagnosis. In the healthy US population, serologic evidence of prior toxoplasmosis infection is very prevalent.
• A small percentage of uveitis patients have syphilis. It can show up as retinal vasculitis or chorioretinitis, which are examples of posterior uveitis. Because of its potential for treatment, syphilis must be identified.
• In the western world, tuberculosis is a rare cause of uveitis. A granulomatous look of the ocular inflammation, immunosuppression, recent immigration from endemic areas, cachexia, homelessness, and active tuberculosis elsewhere in the body should all be taken into consideration.
The link between cat-scratch illness (B. henselae) and uveitis (neuroretinitis) is becoming more widely acknowledged.
•
• Keratouveitis, an inflammation, can be brought on by HSV and VZV.
of the cornea as well as mostly anterior uveitis. Acute retinal necrosis (ARN), a necrotizing retinitis, can also be brought on by either HSV or VZV.
• Histoplasma capsulatum can enter the bloodstream and go to the choroid after being inhaled in endemic regions (the Ohio–Mississippi River Valley). Ocular symptoms including peripapillary atrophy, tiny, round fundus lesions with little to no inflammation, and the early-life macular choroidal neovascular membranes that make up the POHS have all been connected to exposure.
• When making an etiologic diagnosis, geographic factors are important. For instance, leptospirosis and tuberculosis are significant factors to take into account in developing nations when uveitis occurs, as these conditions are uncommon in western nations.
COMMON CONNECTED CIRCUMSTANCES
Sarcoidosis, systemic lupus erythematosus, seronegative spondyloarthropathies, and other connective tissue diseases often appear with or are linked to uveitis.
History of Diagnosis
• Light sensitivity (photophobia) and dull periorbital pain, with or without reduced vision, are common symptoms of anterior uveitis. Similar to juvenile idiopathic arthritis, uveitis in children can occur without obvious symptoms, yet it can have a serious impact on their vision.
Similar symptoms, such as vitreous opacities (floaters) and typically impaired vision, are present in posterior uveitis.
MEDICAL EXAMINATION
• Slit-lamp examination shows inflammatory cells in the anterior chamber, and redness of the eye (conjunctival injection) is typically evident in anterior uveitis.
•
•
The diagnosis of herpetic keratouveitis can be made with the help of cutaneous vesicles, distinctive corneal alterations, decreased corneal sensitivity, increased intraocular pressure, and iris atrophy.
Inflammatory cells or even larger cell aggregates are present in posterior and intermediate uveitis.
in the vitreous cavity (snowballs).
· People with impaired immune systems frequently don't constitute
an inflammatory reaction, even when there is substantial
involvement of the eyes.
• Typically, Toxoplasma chorioretinitis manifests as big,
Adjacent to old chorioretinal scars are smooth, yellow-white retinal lesions accompanied by vitreous inflammation. Multiple, bilateral lesions linked to encephalitis can occur in immunocompromised persons.
• Because of the patient's weakened immune system, CMV retinitis manifests as hemorrhagic necrotizing retinitis with minimal inflammation.
• In immunocompetent patients, HSV, VZV, and infrequently CMV can result in acute retinal necrosis, a widespread unilateral or bilateral necrotizing nonhemorrhagic retinitis. It is frequently linked to trigeminal zoster or orolabial HSV. Widespread, light gray peripheral lesions are found on ophthalmologic examination. If left untreated, the lesions spread quickly.
PORN, a subtype of necrotizing rapidly progressive retinitis, primarily affects patients with impaired immune systems. VZV is the most often isolated viral pathogen.
• Focused white choroidal lesions that extend into the retina are the hallmark of Candida chorioretinitis. The phrase "endogenous fungal endophthalmitis" is more acceptable if the vitreous is affected (see Chapter
"Endophthalmitis."
• B was once believed to be idiopathic. Henselae is a cause.
of cat scratch disease-related neuroretinitis. Swelling of the optic disk, peripapillary and macular hard exudates (macular star), and frequently vitreous cells are the hallmarks of neuroretinitis.
• Several yellow-white choroidal nodules up to half the disk diameter in size and with hazy borders are visible in uveitis owing to tuberculosis. Additionally, patients may experience anterior granulomatous uveitis concurrently.
• If a tick bite history is obtained, a range of ocular symptoms, such as intermediate uveitis, conjunctivitis, keratitis, double vision due to cranial nerve involvement, or disc edema due to optic neuritis, should be anticipated.
Tests for Diagnosis and Interpretation
Lab
First laboratory testing
• Slit-lamp examination is necessary to detect inflammatory cells floating in the aqueous humor and/or deposited on the corneal endothelium (keratic precipitates) in order to diagnose anterior uveitis (iritis and iridocyclitis).
• Involvement of the posterior (intermediate)
The best way to document uveitis is with a dilated fundus.
analysis.
• Because a thorough laboratory analysis may not be conclusive
Unilateral, nongranulomatous, nonrecurrent cases (first episode) with just anterior involvement should be treated symptomatically with topical prednisolone and cycloplegics without additional workup in as many as one-third of cases, even at tertiary uveitis referral facilities.
• The following procedures should be performed on patients with posterior uveitis:
A full blood count that includes differential
Syphilis serology (FTA-ABS and VDRL) - Toxoplasma antibody titer
Assessment for tuberculosis (chest radiograph and PPD skin test)
• A thorough history, physical examination, and consideration of particular ocular characteristics should direct any additional diagnostic workup.
• A considerable percentage of patients with tertiary syphilis may have negative VDRL results. In addition, pregnancy, intravenous drug misuse, TB, rickettsial infection, nonsyphilis treponemal infection, and endocarditis have all been linked to false positive nontreponemal screening tests (VDRL& RPR). As a result, for accurate interpretation, a reactive nontreponemal test must always be verified by a certain treponemal test (FTA-ABS).
• Primary toxoplasmosis can be diagnosed with IgM-positive and IgG-negative serology; toxoplasmosis is unlikely to be diagnosed if both IgM and IgG are negative. In order to diagnose a reactivation of ocular toxoplasmosis, toxoplasma IgG titers show a four-fold increase that peaks 6–8 weeks after infection and decreases over the next two years, but they are detectable for life.
• Because serology is not always accurate, the diagnosis of CMV chorioretinitis in susceptible patients is established on clinical grounds.
In situations of necrotizing retinitis, which is sometimes aggravated by spontaneous retinal detachments, a vitreous biopsy submitted for cytology or exposed to PCR for viral infections (CMV, HSV, and VZV) can be beneficial. However, the procedure is not risk-free.
• A number of conditions (such as toxocariasis, B. henselae, brucellosis, leptospirosis, HSV, CMV, VZV, EBV, HIV, HTLV, Lyme disease, histoplasmosis, etc.) can benefit from serum antibody testing.
The examination of some individuals may be aided by lumbar puncture, neuroimaging, skin lesion biopsy, ACE levels, chest X-rays, and colonoscopy (e.g., toxoplasmosis, inflammatory bowel disease, neurosyphilis, or sarcoidosis).
Follow-up and Particular Points to Remember
Regular follow-up exams are necessary until a diagnosis is made or a treatment response is recorded.
Imagining
• Chest CT scans or X-rays can offer diagnostic hints for many conditions (tumor, histoplasmosis, sarcoidosis, tuberculosis, etc.).
• Among other conditions, rheumatoid arthritis, lupus, gonorrhea, and seronegative spondyloarthropathies linked to HLA-B27 can benefit from joint films.
• To confirm probable sarcoidosis, gallium scans are used.
Diagnostic Techniques and Other
Under sterile conditions, a vitreous tap can be carried out, and the samples ought to be sent for cytology and PCR to check for certain pathogens (see above).
Pathological Results
A diagnostic biopsy is rarely required with today's diagnostic methods, and it may be limited to cases of necrotizing retinitis (ARN) that are worsened by retinal detachment, in which case tissue is taken during surgical repair. Intranuclear in the early stages
Characteristic are inclusions created by herpesvirus particles that are multiplying.
DISTINCTIVE DIAGNOSIS
As previously discussed under "Etiology," there is a wide range of differential diagnoses between chorioretinitis and ocular inflammation (uveitis).
MEDICATION FOR TREATMENT
First Phrase
• The goal of treating anterior uveitis with topical steroids (prednisolone acetate 1%) is to minimize scarring and inflammation. By using topical cycloplegic medicines (cyclopentolate 1%) to treat mydriasis, discomfort and photophobia are decreased and synechiae development is inhibited.
• When infectious uveitis occurs, etiologic therapy is required. After starting antibiotic treatment, topical or systemic steroids might be administered to reduce the inflammatory response.
• Immunocompetent patients with ocular toxoplasmosis do not require therapy unless they have lesions close to the macula or optic nerve that endanger their vision. Pyrimethamine (200 mg p.o. loading dosage and then 25 mg p.o. per day) combined with folinic acid (10 mg p.o. twice weekly) and sulfadiazine (2 g p.o. loading dose and then 1 g p.o. q.i.d.) or clindamycin (150–450 mg p.o. q.i.d.) is used in these situations.
suggested. It is possible to add prednisone (0.5–1 mg/kg p.o. each day) 24 hours after starting the antibiotic treatment.
• Some authors recommend CSF testing and treatment with crystalline penicillin G (2–4 million units i.v. every 4 hours) for 10–14 days, followed by benzathine penicillin (2.4 million units i.m. weekly) for 3 weeks, because they believe that any type of ocular inflammation (anterior, intermediate, posterior uveitis, retinitis, or optic neuritis) in syphilis is neurosyphilis. Others think that neurosyphilis is limited to involvement of the retina or optic nerve. In order to track therapy response, CSF should be collected and sent for VDRL. According to current CDC guidelines, if CSF VDRL is positive, neurosyphilis is present regardless of ocular involvement. If high protein or white cell counts are seen in the CSF of specific patients, the diagnosis is deemed likely. HIV patients with syphilis frequently experience treatment failures, but it should be emphasized that HIV patients may still exhibit CSF abnormalities (see pertinent chapters).
• A two-week treatment trial of isoniazid (300 mg p.o. per day) and pyridoxine (10 mg p.o. per day) may be administered to individuals with suspected TB-related uveitis.
• Starting HAART is the most crucial step in treating CMV retinitis in order to achieve immunological
recuperation, which could take many weeks to accomplish. CMV-specific therapy is required during that time to prevent vision loss and slow the progression of necrotizing retinitis.
• Ganciclovir, foscarnet, and cidofovir are the three antiviral medications that work well for treating CMV retinitis. Ganciclovir's intravenous induction dose is 5 mg/kg. b.i.d. for 14–21 days; 5 mg/kg i.v. is the maintenance dosage. daily, seven days a week, or 6 mg/kg intravenously. five days a week, every day. Foscarnet's intravenous induction dose is 90 mg/kg. b.i.d. for 14–21 days; 90–120 mg/kg i.v. is the maintenance dose. every day. Cidofovir's intravenous induction dose is 5 mg/kg. per week for two weeks; the maintenance dose is administered at two-week intervals and is the same. The oral prodrug valganciclovir, which is administered at doses of 900 mg p.o., just became accessible and has a bioavailability comparable to that of intravenous ganciclovir. b.i.d. during the first 21 days of induction therapy; valganciclovir dosage is lowered to 900 mg p.o. after this time. daily for the purpose of maintenance therapy. Patients who continue to be immunosuppressed should continue their therapy.
• After the CD4+ count reaches 100–150 cells/μL for a prolonged duration of 3–6 months and the CMV retinitis stays dormant, anti-CMV treatment can be stopped; nevertheless, ongoing surveillance for disease reactivation is advised.
• Treatment options for relapse or resistant CMV retinitis include
intraocular injections (cidofovir [administered less regularly], ganciclovir, foscarnet, and fomivirsen) or with the
sustained-release ganciclovir implant (Vitrasert®, Bausch & Lomb, San Dimas, CA) that releases medication for up to eight months after being placed through the pars plana. Most specialists believe that the ganciclovir implant is the best option for people with immediately sight-threatening disease because it is more successful than intravenous ganciclovir in treating CMV retinitis. However, this method necessitates intraocular surgery, which could have negative consequences. A brand-new anti-sense oligonucleotide called fomivirsen is injected into the eye in 0.5 mL doses on days 1 and 15 and then monthly after that (330 μg/0.5 mL).
• Controlling the spread of the CMV infection to other organs or to the other eye is not possible with local therapy.
• For ten to fourteen days, ARN is treated with intravenous acyclovir (1500 mg/m2 of body surface area in three divided doses). To avoid second eye involvement, treatment is continued for a total of 6 weeks with oral valganciclovir (1 g p.o. t.i.d.). To avoid retinal detachment, preventative barrier laser photocoagulation should be taken into consideration.
• In six weeks, cat scratch disease goes away on its own. One possible treatment option is azithromycin (500 mg p.o. q.i.d., followed by four doses of 250 mg p.o. every day). Although the long-term outlook is favorable, some people may experience hardship.
from a minor optic neuropathy that was caused by an infection.
• In POHS, systemic antifungal drugs are not required. The goals of intravitreal anti-VEGF therapy, photocoagulation, and corticosteroids are to lessen the size and effects of the macular choroidal
neovascularization.
Line Two
• It has been demonstrated that trimethoprim + sulfamethoxazole (160/800 mg p.o. b.i.d.) is an effective treatment regimen for CNS toxoplasmosis in AIDS patients. It can also be used to treat ocular toxoplasmosis in patients who cannot tolerate pyrimethamine.
• Aspirin dosages of 125–625 mg PO daily may be taken into consideration in ARN.
• When ganciclovir, foscarnet, and cidofovir are not effective in treating CMV retinitis, fomivirsen is an alternative. In the US, it is no longer accessible.
ADDITIONAL MEDICATION
Referral Issues
The treating ophthalmologist, who can assess the response to treatment, is frequently involved in management choices.
OTHER PROCEDURES AND SURGERY
Only the treatment of problems like cataract, retinal detachment, and ocular glaucoma involves surgery.
Considering the patient
First Stabilization
The majority of uveitis patients are treated as outpatients.
Requirements for Admission
Only patients with extensive ocular involvement who are monocular, socially excluded, or systemically unwell are hospitalized.
PERMANENT CARE
SUMMARY RECOMMENDATIONS
Follow-up is customized.
Monitoring of Patients
In order to control ocular inflammation, some patients with recurrent uveitis require continuous immune modulation, while others require lifelong monitoring. Even infectious uveitis, such as that caused by toxoplasmosis or herpetic keratouveitis, can reactivate ocular inflammation.
A DIET
There are no particular restrictions that are relevant to the sight.
Education of Patients
Particularly in cases of recurrent uveitis, patient education regarding early detection of signs and symptoms of ocular inflammation is crucial because timely treatment is linked to a quicker recovery and
fewer difficulties.
PROGNOSIS
The particular ailment producing chorioretinitis or uveitis determines the prognosis. 79% of patients with ocular toxoplasmosis who are monitored for more than five years will experience recurrences. Of individuals with ocular toxoplasmosis, 24% have been confirmed to have legal blindness in one or both eyes. When compared to conventional anti-CMV therapy alone, HAART has extended the duration of CMV retinitis remission by seven times. Legal blindness has decreased to roughly 6–15% every eye-year in people with CMV retinitis.
DIFFICULTIES
• Long-term use of steroids can contribute to the development of cataracts and glaucoma, which are frequent side effects of chronic ocular inflammation.
• Cystoid macular edema, which alters the normal macular architecture and reduces visual acuity, is another condition that inflammation can induce.
• Up to one-third of patients with CMV retinitis may experience rhegmatogenous retinal detachment. This also holds true for other types of necrotizing retinitis, like PORN and ARN.
ESSENTIALS DESCRIPTION
Any inflammation of the choroid, ciliary body, and iris, which are located between the outer (sclera and cornea) and inner (retina) coats of the eye, is referred to as uveitis.
• There are several types of uveitis:
- Anterior (limited to the anterior chamber and iris)
as ciliary body involvement or iritis, as well as
as iridocyclitis in this instance.
In the interim (should the inflammatory process emerge in the
pars planitis, or peripheral retina
In the event that the inflammatory process develops in the
vitreous and choroid, whether or not they are involved
of the retina
Panuveitis (should the infection disregard any
anatomical limits inside the eye
• Despite not being a component of the uvea, the retina frequently becomes
either directly (retinitis) or indirectly (chorioretinitis) involved in inflammatory eye conditions. Neurotropic organisms like Toxoplasma gondii and herpes viruses are particularly prone to affecting the retina.
• Acute, recurring, and chronic uveitis can be distinguished based on the temporal pattern of ocular involvement; this differentiation is often useful in establishing a precise diagnosis.
The study of epidemiology
The prevalence
• It is estimated that there are 15 to 50 instances of uveitis per 100,000 people each year.
• Up to 10% of all blindness cases in the US are caused by infectious and noninfectious uveitis.
• The majority of uveitis is anterior uveitis, which includes iritis and iridocyclitis.
• In one-third to one-fifth of cases, idiopathic uveitis, no etiologic diagnosis can be made.
• Based on population-based studies, the distribution of uveitis by anatomic site is as follows:
- Front: 73%
Posterior: 22%
Panuveitis: 5%; Intermediate: 1%
• The choroid frequently serves as a trap for blood-borne infections because of its enormous blood flow and architecture. Common choroidal/retinal lesions that also invade the vitreous (endogenous fungal)
Approximately 1% to 2% of patients with invasive Candida species or candidemia develop endophthalmitis. infections.
The frequency
According to estimates, there are roughly 115 instances of infected and noninfectious uveitis for every 100,000 people in the United States. Prevalence figures vary from 75 to 700 instances per 100,000 people worldwide, with poorer nations providing the highest estimates. The length of the study has an impact on prevalence estimates since the longer a group is investigated, the more likely it is that cases of recurrent uveitis will become active.
RISK ELEMENTS
• In patients with AIDS or HIV-unrelated immunosuppression, a drop in the CD4+ T-lymphocyte count below 50 cells/μL is a substantial risk factor for CMV retinitis.
• AIDS is also a risk factor for progressive outer retinal necrosis (PORN), a typical manifestation of necrotizing retinitis linked to VZV.
Genetics
• Despite having a modest positive predictive value, HLA-typing has been widely utilized to diagnose patients with noninfectious uveitis. Therefore, HLA-typing should only be used to validate a particular clinical suspicion.
• When seronegative spondyloarthropathies are present, anterior uveitis is linked to HLA-B27.
• 85–95% of people with Birdshot's chorioretinopathy, a prevalent condition that causes posterior uveitis, have HLA-A29.
• HLA-B51 is around nine times more common in people with Adamantiades-Behcet's illness than in the general population, while HLA-DR2 and HLA-DR15 have been linked to intermediate uveitis.
OVERALL PREVENTION
To the extent that the related illness or infection can be avoided, so can ocular inflammation. For instance, preventing pregnant women with weakened immune systems from consuming raw or undercooked meat and potentially soil-contaminated fruits and vegetables can reduce the incidence of vertically transmitted ocular toxoplasmosis.
Pathophysiology
• Uveitis is typically brought on by an immunological response.
This could be an autoimmune reaction to several uveitogenic ocular antigens (such as Retinal S-Antigen) or a host's reaction to invasive pathogens.
• Autoimmune conditions such rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, and seronegative spondyloarthropathies are often diagnosed in conjunction with uveitis. In certain situations, immune system components that interact with loci in the retina, ciliary body, iris epithelium, or retinal pigmented epithelium may cause uveitis.
Ethiology
Bacterial infections are among the infectious causes of uveitis.
Non-standard mycobacteria
Bejel
Brucellosis
Leptospirosis with cat-scratch disease (Bartonella henselae)
Leprosy
Whipple's disease, tuberculosis, syphilis, nocardiosis, and Lyme illness
– Spreading
CMV, or cytomegalovirus
EBV, or Epstein-Barr virus
HSV, or herpes simplex virus
VZV, or varicella zoster virus
Mumps, human T cell leukemia virus, and human immunodeficiency virus (HIV)
Rubella
Rubeola
The West Nile virus
Fungi-induced Aspergillosis
Coccidiomycosis, Cryptococcosis, Candidiasis, and Blastomycosis
Presumed Ocular Histoplasmosis Syndrome (POHS): Histoplasmosis
Boydii pseudoallescheria
The parasitic disease sporotrichosis
Acanthamoeba (causes intraocular inflammation and keratitis)
Pneumocystis carinii, Onchocerciasis, Cysticercosis, and Toxocariasis
In western countries, toxoplasmosis is the most frequent cause of posterior uveitis.
• One prominent cause of chorioretinitis is CMV retinitis, which is becoming less common in the HAART era and is typically linked to advanced HIV infection. Up to 30% of AIDS patients would acquire CMV retinitis prior to the availability of HAART.
• In healthy hosts, toxoplasmosis is a surprisingly frequent cause of uveitis. It is thought to be a congenitally acquired infection reactivating. Serology-supported typical chorioretinal lesions are used to make the diagnosis. In the healthy US population, serologic evidence of prior toxoplasmosis infection is very prevalent.
• A small percentage of uveitis patients have syphilis. It can show up as retinal vasculitis or chorioretinitis, which are examples of posterior uveitis. Because of its potential for treatment, syphilis must be identified.
• In the western world, tuberculosis is a rare cause of uveitis. A granulomatous look of the ocular inflammation, immunosuppression, recent immigration from endemic areas, cachexia, homelessness, and active tuberculosis elsewhere in the body should all be taken into consideration.
The link between cat-scratch illness (B. henselae) and uveitis (neuroretinitis) is becoming more widely acknowledged.
•
• Keratouveitis, an inflammation, can be brought on by HSV and VZV.
of the cornea as well as mostly anterior uveitis. Acute retinal necrosis (ARN), a necrotizing retinitis, can also be brought on by either HSV or VZV.
• Histoplasma capsulatum can enter the bloodstream and go to the choroid after being inhaled in endemic regions (the Ohio–Mississippi River Valley). Ocular symptoms including peripapillary atrophy, tiny, round fundus lesions with little to no inflammation, and the early-life macular choroidal neovascular membranes that make up the POHS have all been connected to exposure.
• When making an etiologic diagnosis, geographic factors are important. For instance, leptospirosis and tuberculosis are significant factors to take into account in developing nations when uveitis occurs, as these conditions are uncommon in western nations.
COMMON CONNECTED CIRCUMSTANCES
Sarcoidosis, systemic lupus erythematosus, seronegative spondyloarthropathies, and other connective tissue diseases often appear with or are linked to uveitis.
History of Diagnosis
• Light sensitivity (photophobia) and dull periorbital pain, with or without reduced vision, are common symptoms of anterior uveitis. Similar to juvenile idiopathic arthritis, uveitis in children can occur without obvious symptoms, yet it can have a serious impact on their vision.
Similar symptoms, such as vitreous opacities (floaters) and typically impaired vision, are present in posterior uveitis.
MEDICAL EXAMINATION
• Slit-lamp examination shows inflammatory cells in the anterior chamber, and redness of the eye (conjunctival injection) is typically evident in anterior uveitis.
•
•
The diagnosis of herpetic keratouveitis can be made with the help of cutaneous vesicles, distinctive corneal alterations, decreased corneal sensitivity, increased intraocular pressure, and iris atrophy.
Inflammatory cells or even larger cell aggregates are present in posterior and intermediate uveitis.
in the vitreous cavity (snowballs).
· People with impaired immune systems frequently don't constitute
an inflammatory reaction, even when there is substantial
involvement of the eyes.
• Typically, Toxoplasma chorioretinitis manifests as big,
Adjacent to old chorioretinal scars are smooth, yellow-white retinal lesions accompanied by vitreous inflammation. Multiple, bilateral lesions linked to encephalitis can occur in immunocompromised persons.
• Because of the patient's weakened immune system, CMV retinitis manifests as hemorrhagic necrotizing retinitis with minimal inflammation.
• In immunocompetent patients, HSV, VZV, and infrequently CMV can result in acute retinal necrosis, a widespread unilateral or bilateral necrotizing nonhemorrhagic retinitis. It is frequently linked to trigeminal zoster or orolabial HSV. Widespread, light gray peripheral lesions are found on ophthalmologic examination. If left untreated, the lesions spread quickly.
PORN, a subtype of necrotizing rapidly progressive retinitis, primarily affects patients with impaired immune systems. VZV is the most often isolated viral pathogen.
• Focused white choroidal lesions that extend into the retina are the hallmark of Candida chorioretinitis. The phrase "endogenous fungal endophthalmitis" is more acceptable if the vitreous is affected (see Chapter
"Endophthalmitis."
• B was once believed to be idiopathic. Henselae is a cause.
of cat scratch disease-related neuroretinitis. Swelling of the optic disk, peripapillary and macular hard exudates (macular star), and frequently vitreous cells are the hallmarks of neuroretinitis.
• Several yellow-white choroidal nodules up to half the disk diameter in size and with hazy borders are visible in uveitis owing to tuberculosis. Additionally, patients may experience anterior granulomatous uveitis concurrently.
• If a tick bite history is obtained, a range of ocular symptoms, such as intermediate uveitis, conjunctivitis, keratitis, double vision due to cranial nerve involvement, or disc edema due to optic neuritis, should be anticipated.
Tests for Diagnosis and Interpretation
Lab
First laboratory testing
• Slit-lamp examination is necessary to detect inflammatory cells floating in the aqueous humor and/or deposited on the corneal endothelium (keratic precipitates) in order to diagnose anterior uveitis (iritis and iridocyclitis).
• Involvement of the posterior (intermediate)
The best way to document uveitis is with a dilated fundus.
analysis.
• Because a thorough laboratory analysis may not be conclusive
Unilateral, nongranulomatous, nonrecurrent cases (first episode) with just anterior involvement should be treated symptomatically with topical prednisolone and cycloplegics without additional workup in as many as one-third of cases, even at tertiary uveitis referral facilities.
• The following procedures should be performed on patients with posterior uveitis:
A full blood count that includes differential
Syphilis serology (FTA-ABS and VDRL) - Toxoplasma antibody titer
Assessment for tuberculosis (chest radiograph and PPD skin test)
• A thorough history, physical examination, and consideration of particular ocular characteristics should direct any additional diagnostic workup.
• A considerable percentage of patients with tertiary syphilis may have negative VDRL results. In addition, pregnancy, intravenous drug misuse, TB, rickettsial infection, nonsyphilis treponemal infection, and endocarditis have all been linked to false positive nontreponemal screening tests (VDRL& RPR). As a result, for accurate interpretation, a reactive nontreponemal test must always be verified by a certain treponemal test (FTA-ABS).
• Primary toxoplasmosis can be diagnosed with IgM-positive and IgG-negative serology; toxoplasmosis is unlikely to be diagnosed if both IgM and IgG are negative. In order to diagnose a reactivation of ocular toxoplasmosis, toxoplasma IgG titers show a four-fold increase that peaks 6–8 weeks after infection and decreases over the next two years, but they are detectable for life.
• Because serology is not always accurate, the diagnosis of CMV chorioretinitis in susceptible patients is established on clinical grounds.
In situations of necrotizing retinitis, which is sometimes aggravated by spontaneous retinal detachments, a vitreous biopsy submitted for cytology or exposed to PCR for viral infections (CMV, HSV, and VZV) can be beneficial. However, the procedure is not risk-free.
• A number of conditions (such as toxocariasis, B. henselae, brucellosis, leptospirosis, HSV, CMV, VZV, EBV, HIV, HTLV, Lyme disease, histoplasmosis, etc.) can benefit from serum antibody testing.
The examination of some individuals may be aided by lumbar puncture, neuroimaging, skin lesion biopsy, ACE levels, chest X-rays, and colonoscopy (e.g., toxoplasmosis, inflammatory bowel disease, neurosyphilis, or sarcoidosis).
Follow-up and Particular Points to Remember
Regular follow-up exams are necessary until a diagnosis is made or a treatment response is recorded.
Imagining
• Chest CT scans or X-rays can offer diagnostic hints for many conditions (tumor, histoplasmosis, sarcoidosis, tuberculosis, etc.).
• Among other conditions, rheumatoid arthritis, lupus, gonorrhea, and seronegative spondyloarthropathies linked to HLA-B27 can benefit from joint films.
• To confirm probable sarcoidosis, gallium scans are used.
Diagnostic Techniques and Other
Under sterile conditions, a vitreous tap can be carried out, and the samples ought to be sent for cytology and PCR to check for certain pathogens (see above).
Pathological Results
A diagnostic biopsy is rarely required with today's diagnostic methods, and it may be limited to cases of necrotizing retinitis (ARN) that are worsened by retinal detachment, in which case tissue is taken during surgical repair. Intranuclear in the early stages
Characteristic are inclusions created by herpesvirus particles that are multiplying.
DISTINCTIVE DIAGNOSIS
As previously discussed under "Etiology," there is a wide range of differential diagnoses between chorioretinitis and ocular inflammation (uveitis).
MEDICATION FOR TREATMENT
First Phrase
• The goal of treating anterior uveitis with topical steroids (prednisolone acetate 1%) is to minimize scarring and inflammation. By using topical cycloplegic medicines (cyclopentolate 1%) to treat mydriasis, discomfort and photophobia are decreased and synechiae development is inhibited.
• When infectious uveitis occurs, etiologic therapy is required. After starting antibiotic treatment, topical or systemic steroids might be administered to reduce the inflammatory response.
• Immunocompetent patients with ocular toxoplasmosis do not require therapy unless they have lesions close to the macula or optic nerve that endanger their vision. Pyrimethamine (200 mg p.o. loading dosage and then 25 mg p.o. per day) combined with folinic acid (10 mg p.o. twice weekly) and sulfadiazine (2 g p.o. loading dose and then 1 g p.o. q.i.d.) or clindamycin (150–450 mg p.o. q.i.d.) is used in these situations.
suggested. It is possible to add prednisone (0.5–1 mg/kg p.o. each day) 24 hours after starting the antibiotic treatment.
• Some authors recommend CSF testing and treatment with crystalline penicillin G (2–4 million units i.v. every 4 hours) for 10–14 days, followed by benzathine penicillin (2.4 million units i.m. weekly) for 3 weeks, because they believe that any type of ocular inflammation (anterior, intermediate, posterior uveitis, retinitis, or optic neuritis) in syphilis is neurosyphilis. Others think that neurosyphilis is limited to involvement of the retina or optic nerve. In order to track therapy response, CSF should be collected and sent for VDRL. According to current CDC guidelines, if CSF VDRL is positive, neurosyphilis is present regardless of ocular involvement. If high protein or white cell counts are seen in the CSF of specific patients, the diagnosis is deemed likely. HIV patients with syphilis frequently experience treatment failures, but it should be emphasized that HIV patients may still exhibit CSF abnormalities (see pertinent chapters).
• A two-week treatment trial of isoniazid (300 mg p.o. per day) and pyridoxine (10 mg p.o. per day) may be administered to individuals with suspected TB-related uveitis.
• Starting HAART is the most crucial step in treating CMV retinitis in order to achieve immunological
recuperation, which could take many weeks to accomplish. CMV-specific therapy is required during that time to prevent vision loss and slow the progression of necrotizing retinitis.
• Ganciclovir, foscarnet, and cidofovir are the three antiviral medications that work well for treating CMV retinitis. Ganciclovir's intravenous induction dose is 5 mg/kg. b.i.d. for 14–21 days; 5 mg/kg i.v. is the maintenance dosage. daily, seven days a week, or 6 mg/kg intravenously. five days a week, every day. Foscarnet's intravenous induction dose is 90 mg/kg. b.i.d. for 14–21 days; 90–120 mg/kg i.v. is the maintenance dose. every day. Cidofovir's intravenous induction dose is 5 mg/kg. per week for two weeks; the maintenance dose is administered at two-week intervals and is the same. The oral prodrug valganciclovir, which is administered at doses of 900 mg p.o., just became accessible and has a bioavailability comparable to that of intravenous ganciclovir. b.i.d. during the first 21 days of induction therapy; valganciclovir dosage is lowered to 900 mg p.o. after this time. daily for the purpose of maintenance therapy. Patients who continue to be immunosuppressed should continue their therapy.
• After the CD4+ count reaches 100–150 cells/μL for a prolonged duration of 3–6 months and the CMV retinitis stays dormant, anti-CMV treatment can be stopped; nevertheless, ongoing surveillance for disease reactivation is advised.
• Treatment options for relapse or resistant CMV retinitis include
intraocular injections (cidofovir [administered less regularly], ganciclovir, foscarnet, and fomivirsen) or with the
sustained-release ganciclovir implant (Vitrasert®, Bausch & Lomb, San Dimas, CA) that releases medication for up to eight months after being placed through the pars plana. Most specialists believe that the ganciclovir implant is the best option for people with immediately sight-threatening disease because it is more successful than intravenous ganciclovir in treating CMV retinitis. However, this method necessitates intraocular surgery, which could have negative consequences. A brand-new anti-sense oligonucleotide called fomivirsen is injected into the eye in 0.5 mL doses on days 1 and 15 and then monthly after that (330 μg/0.5 mL).
• Controlling the spread of the CMV infection to other organs or to the other eye is not possible with local therapy.
• For ten to fourteen days, ARN is treated with intravenous acyclovir (1500 mg/m2 of body surface area in three divided doses). To avoid second eye involvement, treatment is continued for a total of 6 weeks with oral valganciclovir (1 g p.o. t.i.d.). To avoid retinal detachment, preventative barrier laser photocoagulation should be taken into consideration.
• In six weeks, cat scratch disease goes away on its own. One possible treatment option is azithromycin (500 mg p.o. q.i.d., followed by four doses of 250 mg p.o. every day). Although the long-term outlook is favorable, some people may experience hardship.
from a minor optic neuropathy that was caused by an infection.
• In POHS, systemic antifungal drugs are not required. The goals of intravitreal anti-VEGF therapy, photocoagulation, and corticosteroids are to lessen the size and effects of the macular choroidal
neovascularization.
Line Two
• It has been demonstrated that trimethoprim + sulfamethoxazole (160/800 mg p.o. b.i.d.) is an effective treatment regimen for CNS toxoplasmosis in AIDS patients. It can also be used to treat ocular toxoplasmosis in patients who cannot tolerate pyrimethamine.
• Aspirin dosages of 125–625 mg PO daily may be taken into consideration in ARN.
• When ganciclovir, foscarnet, and cidofovir are not effective in treating CMV retinitis, fomivirsen is an alternative. In the US, it is no longer accessible.
ADDITIONAL MEDICATION
Referral Issues
The treating ophthalmologist, who can assess the response to treatment, is frequently involved in management choices.
OTHER PROCEDURES AND SURGERY
Only the treatment of problems like cataract, retinal detachment, and ocular glaucoma involves surgery.
Considering the patient
First Stabilization
The majority of uveitis patients are treated as outpatients.
Requirements for Admission
Only patients with extensive ocular involvement who are monocular, socially excluded, or systemically unwell are hospitalized.
PERMANENT CARE
SUMMARY RECOMMENDATIONS
Follow-up is customized.
Monitoring of Patients
In order to control ocular inflammation, some patients with recurrent uveitis require continuous immune modulation, while others require lifelong monitoring. Even infectious uveitis, such as that caused by toxoplasmosis or herpetic keratouveitis, can reactivate ocular inflammation.
A DIET
There are no particular restrictions that are relevant to the sight.
Education of Patients
Particularly in cases of recurrent uveitis, patient education regarding early detection of signs and symptoms of ocular inflammation is crucial because timely treatment is linked to a quicker recovery and
fewer difficulties.
PROGNOSIS
The particular ailment producing chorioretinitis or uveitis determines the prognosis. 79% of patients with ocular toxoplasmosis who are monitored for more than five years will experience recurrences. Of individuals with ocular toxoplasmosis, 24% have been confirmed to have legal blindness in one or both eyes. When compared to conventional anti-CMV therapy alone, HAART has extended the duration of CMV retinitis remission by seven times. Legal blindness has decreased to roughly 6–15% every eye-year in people with CMV retinitis.
DIFFICULTIES
• Long-term use of steroids can contribute to the development of cataracts and glaucoma, which are frequent side effects of chronic ocular inflammation.
• Cystoid macular edema, which alters the normal macular architecture and reduces visual acuity, is another condition that inflammation can induce.
• Up to one-third of patients with CMV retinitis may experience rhegmatogenous retinal detachment. This also holds true for other types of necrotizing retinitis, like PORN and ARN.
- Published on
Infectious Disease – Campylobacter Infections
CAMPYLOBACTER INFECTIONS
BASIC DESCRIPTION
• Campylobacter species are a significant foodborne etiological agent of diarrheal diseases in both developed and developing nations. • Postinfectious sequelae of Campylobacter infection encompass Guillain–Barré syndrome and reactive arthritis.
EPIDEMIOLOGY
Incidence
Campylobacteriosis is a global zoonotic disease, and Campylobacter enteritis is a prevalent kind of acute gastroenteritis in North America.
C. jejuni infections manifest throughout the year in the United States and other industrialized nations, with a pronounced surge during the summer and early autumn months.
• As much as 90% of broiler birds exhibit contamination.
Campylobacter bacteria are readily transmitted by contaminated drinking water and unpasteurized milk. Certain instances are linked to the preparation of contaminated food. However, the epidemiology of the infection in poor nations differs, as C. jejuni is frequently isolated from asymptomatic individuals and is particularly prevalent during the initial five years of life.
RISK FACTORS
In wealthy nations, the intake of undercooked poultry is believed to account for over fifty percent of sporadic Campylobacter infection cases.
HIV-positive individuals exhibit an elevated susceptibility to infections.
Genetics
Reactive arthritis may manifest several weeks after infection in individuals possessing HLA-B27 histocompatibility antigens.
GENERAL PREVENTION • Campylobacter can be eradicated by roasting poultry and other meats to an internal temperature of 82°C (180°F). The temperature at which the meat ceases to exhibit a pink hue and the juices flow clear is specified. Poultry and other meats must be prepared separately from other items, both in commercial establishments and domestic settings.
Countertops, utensils, towels, and aprons utilized in the preparation of chicken and other meats must be cleansed with hot water and soap prior to being employed for other items, especially those that will not undergo cooking.
Handwashing is crucial.
Suspected cases, especially those linked to additional instances within family or acquaintances, must be reported immediately to the local health authority.
Pathophysiology
The incubation period varies from 1 to 7 days.
• A mere 500 germs can induce sickness in certain persons.
The proven correlation between Campylobacter infection and Guillain–Barré syndrome is believed to stem from molecular mimicry, due to the structural similarity of antigens shared by Campylobacter and peripheral nerves.
ETIOLOGY • Campylobacter jejuni and Campylobacter coli are the primary etiological agents of Campylobacter infection in humans.
C. fetus is a significant etiological agent of systemic infection and chronic bacteremia in immunocompromised individuals.
However, it is not a significant cause of enteritis in immunocompetent individuals.
HISTORY OF DIAGNOSIS
• Acute enteritis is the predominant manifestation of C. jejuni infection. • Symptoms may persist for a duration ranging from 1 day to over 1 week.
• Frequently, a prodrome presents with fever, headache, myalgia, and malaise.
• The predominant symptoms are as follows:
- Abdominal discomfort (often cramping) – Diarrhea – Fever (often low-grade but may reach 40°C or higher)
Malaise
• Diarrhea can range from loose stools to profuse watery stools or visibly bloody stools.
• Infections caused by C. fetal might result in intermittent diarrhea or general abdominal discomfort without localized symptoms. • C. fetus may also lead to a lengthy relapsing illness marked by fever, chills, and myalgia, with no identifiable source of infection.
PHYSICAL EXAMINATION
• Physical examination results in the majority of Campylobacter enteritis cases are nonspecific, typically revealing minor abdominal pain.
• In few instances, intense stomach discomfort may cause Campylobacter enteritis to resemble appendicitis (pseudoappendicitis); nevertheless, typical physical indications of peritonitis, such as guarding and rebound soreness, are infrequent.
DIAGNOSTIC TESTS AND INTERPRETATION Lab
In numerous instances of Campylobacter enteritis, a modest leukocytosis accompanied by an elevation in neutrophils is observed.
The diagnosis of Campylobacter jejuni infection is often established through a positive stool culture.
• Campylobacter species are extracted from fecal samples utilizing microaerobic incubation conditions and selective methods that inhibit the proliferation of competing microorganisms. • Bacteremia occurs in less than 1% of individuals with C. jejuni infection.
DIFFERENTIAL DIAGNOSIS
The diagnosis may be inferred from the symptoms.
This can be readily verified using stool culture.
INITIAL THERAPEUTIC AGENT
• Antimicrobial therapy is warranted for individuals with severe or prolonged symptoms, or those with risk factors for consequences, including pregnancy, immunocompromising diseases, or advanced age, as most infections are self-limiting.
Ciprofloxacin (500 mg orally, twice day for 5–7 days) is regarded as a first-line treatment. Nonetheless, the resistance of Campylobacter to quinolones is escalating.
Macrolides, such as erythromycin, represent an additional suitable first-line therapy. The advised dosage for adults is 250 mg orally four times daily for 5–7 days; for children, the suggested dosage is 30–50 mg/kg per day in divided doses for the same duration.
Campylobacter strains obtained in underdeveloped nations exhibit a higher propensity for erythromycin resistance.
The requirement for addressing septic or bacteremic episodes with drugs other than ciprofloxacin has not been determined. For patients with severe toxicity-
Prolonged treatment with gentamicin or imipenem is warranted.
Second Line
Most isolates of C. jejuni and C. coli exhibit resistance to cephalosporins and penicillin; hence, these drugs should be avoided.
• The susceptibility to sulfonamides and metronidazole is inconsistent. Treatment with antimicrobial drugs does not extend the carriage of C. jejuni, unlike Salmonella infections; rather, it typically eradicates carriage within 72 hours in the majority of patients.
SUPPLEMENTARY THERAPY
Comprehensive Strategies
Evaluation of hydration status and suitable fluid and electrolyte replenishment are necessary.
Supplementary Treatments
• The administration of an antimotility agent may extend the duration of symptoms unless it is administered together with an antibiotic. • Antimotility treatments are contraindicated in pediatric patients.
INPATIENT CONSIDERATIONS
Admission Criteria • A limited number of patients with Campylobacter enteritis necessitate hospitalization. • Possible reasons for admission encompass moderate to severe dehydration, intense pain, systemic sickness, or complications (elaborated below).
Intravenous Fluids
Only isotonic solutions should be administered to individuals experiencing severe dehydration.
CONTINUING CARE POST-TREATMENT RECOMMENDATIONS
Postinfectious consequences of Campylobacter enteritis typically manifest within two months following the acute infection.
Patient Surveillance
Patients experiencing recurrent diarrhea should be closely watched through meticulous documentation of fluid intake and output, as well as for indications of dehydration.
DIET
Patients with enteritis may maintain a regular diet as tolerated.
PROGNOSIS
• The majority of patients achieve complete recovery from Campylobacter enteritis, either spontaneously or with suitable antimicrobial treatment.
• Campylobacter infections are the most prevalent.
While Campylobacter enteritis is a well acknowledged antecedent of Guillain–Barré syndrome, it is crucial to note that only 1 in every 1000 people with this condition eventually develops GBS, indicating a minimal risk for any individual.
• Infection with C. fetus may be fatal for individuals with chronic compensated conditions such as cirrhosis or diabetes mellitus.
consequences • The primary postinfectious consequences of Campylobacter enteritis in immunocompetent individuals are reactive arthritis and Guillain–Barré syndrome, as previously mentioned.
• • • • •
Campylobacter infections can be fatal in immunocompromised persons.
Campylobacter jejuni may induce septic abortion.
Reports of C. jejuni infections presenting with acute cholecystitis, pancreatitis, and cystitis have been sporadic.
Campylobacter jejuni has been linked to an intestinal immunoproliferative disease characterized by malabsorption and protein-losing enteropathy.
C. fetal infections demonstrate a preference for arterial locations; vascular necrosis is observed in patients with endocarditis and pericarditis.
CNS infections caused by C. fetus manifest in neonates and
individuals of mature age. The prognosis for premature infants is unfavorable; nonetheless, certain full-term neonates have survived infections. The infection presents as meningoencephalitis characterized by polymorphonuclear pleocytosis in the cerebrospinal fluid.
In immunocompromised patients, particularly those with AIDS, bacteremia caused by the "atypical" Campylobacter species occurs rather frequently and may persist indefinitely in the absence of antibiotic treatment.
CAMPYLOBACTER INFECTIONS
BASIC DESCRIPTION
• Campylobacter species are a significant foodborne etiological agent of diarrheal diseases in both developed and developing nations. • Postinfectious sequelae of Campylobacter infection encompass Guillain–Barré syndrome and reactive arthritis.
EPIDEMIOLOGY
Incidence
Campylobacteriosis is a global zoonotic disease, and Campylobacter enteritis is a prevalent kind of acute gastroenteritis in North America.
C. jejuni infections manifest throughout the year in the United States and other industrialized nations, with a pronounced surge during the summer and early autumn months.
• As much as 90% of broiler birds exhibit contamination.
Campylobacter bacteria are readily transmitted by contaminated drinking water and unpasteurized milk. Certain instances are linked to the preparation of contaminated food. However, the epidemiology of the infection in poor nations differs, as C. jejuni is frequently isolated from asymptomatic individuals and is particularly prevalent during the initial five years of life.
RISK FACTORS
In wealthy nations, the intake of undercooked poultry is believed to account for over fifty percent of sporadic Campylobacter infection cases.
HIV-positive individuals exhibit an elevated susceptibility to infections.
Genetics
Reactive arthritis may manifest several weeks after infection in individuals possessing HLA-B27 histocompatibility antigens.
GENERAL PREVENTION • Campylobacter can be eradicated by roasting poultry and other meats to an internal temperature of 82°C (180°F). The temperature at which the meat ceases to exhibit a pink hue and the juices flow clear is specified. Poultry and other meats must be prepared separately from other items, both in commercial establishments and domestic settings.
Countertops, utensils, towels, and aprons utilized in the preparation of chicken and other meats must be cleansed with hot water and soap prior to being employed for other items, especially those that will not undergo cooking.
Handwashing is crucial.
Suspected cases, especially those linked to additional instances within family or acquaintances, must be reported immediately to the local health authority.
Pathophysiology
The incubation period varies from 1 to 7 days.
• A mere 500 germs can induce sickness in certain persons.
The proven correlation between Campylobacter infection and Guillain–Barré syndrome is believed to stem from molecular mimicry, due to the structural similarity of antigens shared by Campylobacter and peripheral nerves.
ETIOLOGY • Campylobacter jejuni and Campylobacter coli are the primary etiological agents of Campylobacter infection in humans.
C. fetus is a significant etiological agent of systemic infection and chronic bacteremia in immunocompromised individuals.
However, it is not a significant cause of enteritis in immunocompetent individuals.
HISTORY OF DIAGNOSIS
• Acute enteritis is the predominant manifestation of C. jejuni infection. • Symptoms may persist for a duration ranging from 1 day to over 1 week.
• Frequently, a prodrome presents with fever, headache, myalgia, and malaise.
• The predominant symptoms are as follows:
- Abdominal discomfort (often cramping) – Diarrhea – Fever (often low-grade but may reach 40°C or higher)
Malaise
• Diarrhea can range from loose stools to profuse watery stools or visibly bloody stools.
• Infections caused by C. fetal might result in intermittent diarrhea or general abdominal discomfort without localized symptoms. • C. fetus may also lead to a lengthy relapsing illness marked by fever, chills, and myalgia, with no identifiable source of infection.
PHYSICAL EXAMINATION
• Physical examination results in the majority of Campylobacter enteritis cases are nonspecific, typically revealing minor abdominal pain.
• In few instances, intense stomach discomfort may cause Campylobacter enteritis to resemble appendicitis (pseudoappendicitis); nevertheless, typical physical indications of peritonitis, such as guarding and rebound soreness, are infrequent.
DIAGNOSTIC TESTS AND INTERPRETATION Lab
In numerous instances of Campylobacter enteritis, a modest leukocytosis accompanied by an elevation in neutrophils is observed.
The diagnosis of Campylobacter jejuni infection is often established through a positive stool culture.
• Campylobacter species are extracted from fecal samples utilizing microaerobic incubation conditions and selective methods that inhibit the proliferation of competing microorganisms. • Bacteremia occurs in less than 1% of individuals with C. jejuni infection.
DIFFERENTIAL DIAGNOSIS
The diagnosis may be inferred from the symptoms.
This can be readily verified using stool culture.
INITIAL THERAPEUTIC AGENT
• Antimicrobial therapy is warranted for individuals with severe or prolonged symptoms, or those with risk factors for consequences, including pregnancy, immunocompromising diseases, or advanced age, as most infections are self-limiting.
Ciprofloxacin (500 mg orally, twice day for 5–7 days) is regarded as a first-line treatment. Nonetheless, the resistance of Campylobacter to quinolones is escalating.
Macrolides, such as erythromycin, represent an additional suitable first-line therapy. The advised dosage for adults is 250 mg orally four times daily for 5–7 days; for children, the suggested dosage is 30–50 mg/kg per day in divided doses for the same duration.
Campylobacter strains obtained in underdeveloped nations exhibit a higher propensity for erythromycin resistance.
The requirement for addressing septic or bacteremic episodes with drugs other than ciprofloxacin has not been determined. For patients with severe toxicity-
Prolonged treatment with gentamicin or imipenem is warranted.
Second Line
Most isolates of C. jejuni and C. coli exhibit resistance to cephalosporins and penicillin; hence, these drugs should be avoided.
• The susceptibility to sulfonamides and metronidazole is inconsistent. Treatment with antimicrobial drugs does not extend the carriage of C. jejuni, unlike Salmonella infections; rather, it typically eradicates carriage within 72 hours in the majority of patients.
SUPPLEMENTARY THERAPY
Comprehensive Strategies
Evaluation of hydration status and suitable fluid and electrolyte replenishment are necessary.
Supplementary Treatments
• The administration of an antimotility agent may extend the duration of symptoms unless it is administered together with an antibiotic. • Antimotility treatments are contraindicated in pediatric patients.
INPATIENT CONSIDERATIONS
Admission Criteria • A limited number of patients with Campylobacter enteritis necessitate hospitalization. • Possible reasons for admission encompass moderate to severe dehydration, intense pain, systemic sickness, or complications (elaborated below).
Intravenous Fluids
Only isotonic solutions should be administered to individuals experiencing severe dehydration.
CONTINUING CARE POST-TREATMENT RECOMMENDATIONS
Postinfectious consequences of Campylobacter enteritis typically manifest within two months following the acute infection.
Patient Surveillance
Patients experiencing recurrent diarrhea should be closely watched through meticulous documentation of fluid intake and output, as well as for indications of dehydration.
DIET
Patients with enteritis may maintain a regular diet as tolerated.
PROGNOSIS
• The majority of patients achieve complete recovery from Campylobacter enteritis, either spontaneously or with suitable antimicrobial treatment.
• Campylobacter infections are the most prevalent.
While Campylobacter enteritis is a well acknowledged antecedent of Guillain–Barré syndrome, it is crucial to note that only 1 in every 1000 people with this condition eventually develops GBS, indicating a minimal risk for any individual.
• Infection with C. fetus may be fatal for individuals with chronic compensated conditions such as cirrhosis or diabetes mellitus.
consequences • The primary postinfectious consequences of Campylobacter enteritis in immunocompetent individuals are reactive arthritis and Guillain–Barré syndrome, as previously mentioned.
• • • • •
Campylobacter infections can be fatal in immunocompromised persons.
Campylobacter jejuni may induce septic abortion.
Reports of C. jejuni infections presenting with acute cholecystitis, pancreatitis, and cystitis have been sporadic.
Campylobacter jejuni has been linked to an intestinal immunoproliferative disease characterized by malabsorption and protein-losing enteropathy.
C. fetal infections demonstrate a preference for arterial locations; vascular necrosis is observed in patients with endocarditis and pericarditis.
CNS infections caused by C. fetus manifest in neonates and
individuals of mature age. The prognosis for premature infants is unfavorable; nonetheless, certain full-term neonates have survived infections. The infection presents as meningoencephalitis characterized by polymorphonuclear pleocytosis in the cerebrospinal fluid.
In immunocompromised patients, particularly those with AIDS, bacteremia caused by the "atypical" Campylobacter species occurs rather frequently and may persist indefinitely in the absence of antibiotic treatment.
- Published on
Infectious Disease - Candidiasis
CANDIDIASIS
DESCRIPTION • Candida is a yeast that constitutes part of the normal flora on the skin and within the gastrointestinal and genitourinary tracts. • Candida species are an emerging cause of bloodstream infections in immunocompromised individuals. • Candida can induce both superficial and systemic infections.
Epidemiology: Candidal infections can affect individuals of all ages; however, they are more prevalent among the elderly, babies, and pregnant women.
• A recent study revealed that up to 9% of bloodstream infections in US hospitals were associated with candidal infection.
– Numerous varieties of Candida exist, with Candida albicans being the primary organism associated with the majority of illnesses. Non-albicans Candida species are rising in prevalence. In a recent specimen
Among over 1400 Candida specimens from hospitalized patients, the most prevalent species following C. albicans were C. parapsilosis, C. glabrata, and C. tropicalis.
RISK FACTORS • Immune suppression/neutropenia (2) • Preexisting conditions associated with immune suppression, including cancer, AIDS, and significant burns
• Extended antibiotic administration • Indwelling intravenous catheter • Chemotherapeutic treatment • Recipients of solid organ and bone marrow transplants • Total parenteral nutrition • Chronic renal insufficiency and hemodialysis • Gastrointestinal perforation • Diabetes mellitus • Gestation • Glucocorticoid therapy
GENERAL PREVENTION
• Prudent use of antibiotics. • Extraction of central venous catheters when no longer required.
PATHOPHYSIOLOGY
• Candidemia may arise from disruptions in mucosal barriers at any location within the gastrointestinal system. • Candidemia may also result from the colonization of intravascular catheter devices.
ETIOLOGY • The genus Candida has over 150 species, with the clinically significant species being C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, and C. lusitaniae. • C. albicans is responsible for over 50% of candidemia cases.
FREQUENTLY CO-OCCURRING CONDITIONS
Immunosuppression due to chemotherapy, HIV/AIDS, solid organ or bone marrow transplantation, neutropenia, or severe underlying conditions necessitating extended ICU admissions with intravenous catheters.
DIAGNOSTIC HISTORY
The clinical presentation and assessment of risk factors are contingent upon the affected organ (e.g., genitourinary and intestinal tracts, brain, skin) and the severity of the disease.
• Vulvovaginal candidiasis: Itching, discomfort, painful urination, painful intercourse, and white, curd-like discharge.
• Oropharyngeal candidiasis: Intermittent discomfort, taste impairment, occasionally asymptomatic.
• Candida esophagitis: Nausea, vomiting, retrosternal chest discomfort, odynophagia, dysphagia.
• Invasive candidiasis: History of immunosuppressive therapy, HIV/AIDS, concomitant malignancy. Mental status alterations may occur if sepsis.
PHYSICAL EXAMINATION
• It is contingent upon the affected organ and the severity of the condition.
• Vulvovaginal candidiasis: Erythema of the vulva or vagina accompanied by a white, curd-like discharge. Occasionally, there is a transparent discharge.
• Oral candidiasis (thrush) and Candida esophagitis: Presence of white plaques on the tongue, hard palate, and soft palate. Frequently results in an erythematous base upon removal. Patients may exhibit esophageal candidiasis in the absence of oral involvement.
Candidemia presents with symptoms ranging from fever to indications of severe sepsis, including hypotension, tachycardia, and alterations in mental status.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• Vulvovaginal candidiasis: Often a clinical diagnosis. The pH of vaginal discharge may vary between 4 and 4.5. Yeast will be observed in microscopic examinations of KOH preparations or wet mounts (3,4).
• Oral candidiasis (thrush): Frequently diagnosed clinically as well. Confirmation can be achieved by examining scrapings on KOH preparations using light microscopy.
Esophageal candidiasis may necessitate endoscopy and biopsy for diagnosis.
Candidemia: Gram staining or proliferation in blood cultures. Candida must not be regarded as a blood contamination.
Susceptibility testing for fluconazole should be conducted in cases of severe infection or in affected people.
ineffective against first-line treatments.
Imaging: Preliminary Strategy
• Neurological assessment: CT scan and MRI of the brain.
• Endocarditis: Transesophageal echocardiography • Esophagitis: Upper endoscopy with biopsy
• Spleen and liver: MRI surpasses CT
Pneumonia: Chest X-ray, Computed Tomography
• Peritonitis: Fluid aspiration guided by CT or ultrasound
Subsequent Actions & Specific Considerations
• For candidemia: Provide general ICU care for stabilization, as death rates may exceed 30–40%.
5–10% of candidemia cases are associated with endophthalmitis complications. Ophthalmology must be consulted in every instance of candidemia.
Diagnostic Procedures/Additional Candida esophagitis: While endoscopy and biopsy represent the definitive method for identifying Candida esophagitis, numerous individuals receive empirical treatment when they exhibit significant symptoms alongside risk factors and oral manifestations.
Candidiasis. It is important to note that oral candidiasis is not a prerequisite for esophageal candidal infections.
Pathological Observations
Yeast exhibiting and lacking pseudohyphae
DIFFERENTIAL DIAGNOSIS
• Oral hairy leukoplakia • Contact dermatitis • Atrophic vaginitis • Bacterial sepsis • Endocarditis • Fever of unknown origin • Cytomegalovirus (CMV) esophagitis
INITIAL THERAPEUTIC AGENT
• Vulvovaginal candidiasis: Various topical treatments are accessible, such as butoconazole cream 5 g/day for 3 days. Oral alternatives are also accessible, including fluconazole 150 mg administered orally as a single dose. Prolonged treatment duration is necessary in severe cases or immunocompromised individuals. Administration of butoconazole cream for 5 to 7 days, or oral fluconazole for up to 7 days, may be required (5–7).
• Oral candidiasis (thrush): Nystatin oral solution (suspension), clotrimazole oral troche, or fluconazole 100–200 mg/day. The therapeutic duration typically spans 5 days following the resolution of symptoms.
Candida esophagitis: Administer Fluconazole 400 mg as a first dose, followed by 200–400 mg daily for a duration of 7–14 days. This can be administered orally, but may be delivered intravenously in certain patients with pronounced dysphagia or odynophagia.
• Candidemia: The selection of empirical therapy is contingent upon the
Candida should undergo culture and sensitivity testing for triazoles (e.g., fluconazole) (8,9). In stable, non-neutropenic patients devoid of antifungal exposure, fluconazole (800 mg intravenously once, followed by 400 mg intravenously daily) is a judicious option. All other patients, including those who are unstable, neutropenic, have prior antifungal exposure, or have experienced recent or extended hospitalizations, should receive empirical treatment with either an echinocandin (caspofungin, micafungin, or anidulafungin), voriconazole, or lipid formulations of amphotericin B. This may be modified to fluconazole if the sample exhibits sensitivity.
C. krusei exhibits resistance to fluconazole.
C. glabrata frequently exhibits resistance to triazoles.
C. parapsilosis isolates have elevated minimum inhibitory concentrations (MICs) to echinocandins.
C. lusitaniae exhibits resistance to amphotericin B. The advised length of antifungal treatment is a minimum of 2 weeks following the negative results of blood cultures. Verify the implementation of adequate "source control" (e.g., intravenous lines have been removed and substituted).
Esophageal candidiasis: In instances of fluconazole resistance, alternative triazoles, including itraconazole, posaconazole, and voriconazole, shown efficacy. An echinocandin, such as caspofungin, micafungin, or anidulafungin, may be utilized in
Patients who are hospitalized can only receive it in intravenous form.
SUPPLEMENTARY THERAPY
Concerns for Referral
Infectious disease specialists should be sought for bloodstream Candida infections and for guidance in managing neutropenic patients.
Pharmacists are invaluable due to the numerous drug interactions associated with antifungal drugs, particularly the triazoles. Exercise caution when concurrently administering warfarin, rifampin, antiepileptic drugs, and sulfonylureas.
OPERATIONS/ADDITIONAL INTERVENTIONS
A surgical consultation is necessary to drain fluid collections infected with Candida species and to manage candidal endocarditis.
INPATIENT CONSIDERATIONS
Criteria for Admission
Patients suspected with candidemia should be hospitalized and administered empiric antifungal medication.
CONTINUING MANAGEMENT POST-TREATMENT GUIDELINES
Patient Surveillance
QT prolongation must be monitored via ECGs in patients administered triazoles (e.g., fluconazole, voriconazole).
• The pharmacy must evaluate potential drug interactions while administering antifungal medicines, particularly triazoles.
• Conduct daily blood cultures in patients with candidemia to confirm sterilization.
• Ophthalmology should evaluate all patients with candidemia for endophthalmitis.
OUTLOOK
Mortality progressively rises in patients with candidemia who have a delay in antifungal treatment. For instance, individuals treated three or more days after confirmed candidemia exhibit mortality rates above 40%.
COMPLICATIONS • Renal failure • Esophageal perforation • Endocarditis • Endophthalmitis • Meningitis • Peritonitis and adhesions • Pericarditis • Abscess • Mortality
CANDIDIASIS
DESCRIPTION • Candida is a yeast that constitutes part of the normal flora on the skin and within the gastrointestinal and genitourinary tracts. • Candida species are an emerging cause of bloodstream infections in immunocompromised individuals. • Candida can induce both superficial and systemic infections.
Epidemiology: Candidal infections can affect individuals of all ages; however, they are more prevalent among the elderly, babies, and pregnant women.
• A recent study revealed that up to 9% of bloodstream infections in US hospitals were associated with candidal infection.
– Numerous varieties of Candida exist, with Candida albicans being the primary organism associated with the majority of illnesses. Non-albicans Candida species are rising in prevalence. In a recent specimen
Among over 1400 Candida specimens from hospitalized patients, the most prevalent species following C. albicans were C. parapsilosis, C. glabrata, and C. tropicalis.
RISK FACTORS • Immune suppression/neutropenia (2) • Preexisting conditions associated with immune suppression, including cancer, AIDS, and significant burns
• Extended antibiotic administration • Indwelling intravenous catheter • Chemotherapeutic treatment • Recipients of solid organ and bone marrow transplants • Total parenteral nutrition • Chronic renal insufficiency and hemodialysis • Gastrointestinal perforation • Diabetes mellitus • Gestation • Glucocorticoid therapy
GENERAL PREVENTION
• Prudent use of antibiotics. • Extraction of central venous catheters when no longer required.
PATHOPHYSIOLOGY
• Candidemia may arise from disruptions in mucosal barriers at any location within the gastrointestinal system. • Candidemia may also result from the colonization of intravascular catheter devices.
ETIOLOGY • The genus Candida has over 150 species, with the clinically significant species being C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, and C. lusitaniae. • C. albicans is responsible for over 50% of candidemia cases.
FREQUENTLY CO-OCCURRING CONDITIONS
Immunosuppression due to chemotherapy, HIV/AIDS, solid organ or bone marrow transplantation, neutropenia, or severe underlying conditions necessitating extended ICU admissions with intravenous catheters.
DIAGNOSTIC HISTORY
The clinical presentation and assessment of risk factors are contingent upon the affected organ (e.g., genitourinary and intestinal tracts, brain, skin) and the severity of the disease.
• Vulvovaginal candidiasis: Itching, discomfort, painful urination, painful intercourse, and white, curd-like discharge.
• Oropharyngeal candidiasis: Intermittent discomfort, taste impairment, occasionally asymptomatic.
• Candida esophagitis: Nausea, vomiting, retrosternal chest discomfort, odynophagia, dysphagia.
• Invasive candidiasis: History of immunosuppressive therapy, HIV/AIDS, concomitant malignancy. Mental status alterations may occur if sepsis.
PHYSICAL EXAMINATION
• It is contingent upon the affected organ and the severity of the condition.
• Vulvovaginal candidiasis: Erythema of the vulva or vagina accompanied by a white, curd-like discharge. Occasionally, there is a transparent discharge.
• Oral candidiasis (thrush) and Candida esophagitis: Presence of white plaques on the tongue, hard palate, and soft palate. Frequently results in an erythematous base upon removal. Patients may exhibit esophageal candidiasis in the absence of oral involvement.
Candidemia presents with symptoms ranging from fever to indications of severe sepsis, including hypotension, tachycardia, and alterations in mental status.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• Vulvovaginal candidiasis: Often a clinical diagnosis. The pH of vaginal discharge may vary between 4 and 4.5. Yeast will be observed in microscopic examinations of KOH preparations or wet mounts (3,4).
• Oral candidiasis (thrush): Frequently diagnosed clinically as well. Confirmation can be achieved by examining scrapings on KOH preparations using light microscopy.
Esophageal candidiasis may necessitate endoscopy and biopsy for diagnosis.
Candidemia: Gram staining or proliferation in blood cultures. Candida must not be regarded as a blood contamination.
Susceptibility testing for fluconazole should be conducted in cases of severe infection or in affected people.
ineffective against first-line treatments.
Imaging: Preliminary Strategy
• Neurological assessment: CT scan and MRI of the brain.
• Endocarditis: Transesophageal echocardiography • Esophagitis: Upper endoscopy with biopsy
• Spleen and liver: MRI surpasses CT
Pneumonia: Chest X-ray, Computed Tomography
• Peritonitis: Fluid aspiration guided by CT or ultrasound
Subsequent Actions & Specific Considerations
• For candidemia: Provide general ICU care for stabilization, as death rates may exceed 30–40%.
5–10% of candidemia cases are associated with endophthalmitis complications. Ophthalmology must be consulted in every instance of candidemia.
Diagnostic Procedures/Additional Candida esophagitis: While endoscopy and biopsy represent the definitive method for identifying Candida esophagitis, numerous individuals receive empirical treatment when they exhibit significant symptoms alongside risk factors and oral manifestations.
Candidiasis. It is important to note that oral candidiasis is not a prerequisite for esophageal candidal infections.
Pathological Observations
Yeast exhibiting and lacking pseudohyphae
DIFFERENTIAL DIAGNOSIS
• Oral hairy leukoplakia • Contact dermatitis • Atrophic vaginitis • Bacterial sepsis • Endocarditis • Fever of unknown origin • Cytomegalovirus (CMV) esophagitis
INITIAL THERAPEUTIC AGENT
• Vulvovaginal candidiasis: Various topical treatments are accessible, such as butoconazole cream 5 g/day for 3 days. Oral alternatives are also accessible, including fluconazole 150 mg administered orally as a single dose. Prolonged treatment duration is necessary in severe cases or immunocompromised individuals. Administration of butoconazole cream for 5 to 7 days, or oral fluconazole for up to 7 days, may be required (5–7).
• Oral candidiasis (thrush): Nystatin oral solution (suspension), clotrimazole oral troche, or fluconazole 100–200 mg/day. The therapeutic duration typically spans 5 days following the resolution of symptoms.
Candida esophagitis: Administer Fluconazole 400 mg as a first dose, followed by 200–400 mg daily for a duration of 7–14 days. This can be administered orally, but may be delivered intravenously in certain patients with pronounced dysphagia or odynophagia.
• Candidemia: The selection of empirical therapy is contingent upon the
Candida should undergo culture and sensitivity testing for triazoles (e.g., fluconazole) (8,9). In stable, non-neutropenic patients devoid of antifungal exposure, fluconazole (800 mg intravenously once, followed by 400 mg intravenously daily) is a judicious option. All other patients, including those who are unstable, neutropenic, have prior antifungal exposure, or have experienced recent or extended hospitalizations, should receive empirical treatment with either an echinocandin (caspofungin, micafungin, or anidulafungin), voriconazole, or lipid formulations of amphotericin B. This may be modified to fluconazole if the sample exhibits sensitivity.
C. krusei exhibits resistance to fluconazole.
C. glabrata frequently exhibits resistance to triazoles.
C. parapsilosis isolates have elevated minimum inhibitory concentrations (MICs) to echinocandins.
C. lusitaniae exhibits resistance to amphotericin B. The advised length of antifungal treatment is a minimum of 2 weeks following the negative results of blood cultures. Verify the implementation of adequate "source control" (e.g., intravenous lines have been removed and substituted).
Esophageal candidiasis: In instances of fluconazole resistance, alternative triazoles, including itraconazole, posaconazole, and voriconazole, shown efficacy. An echinocandin, such as caspofungin, micafungin, or anidulafungin, may be utilized in
Patients who are hospitalized can only receive it in intravenous form.
SUPPLEMENTARY THERAPY
Concerns for Referral
Infectious disease specialists should be sought for bloodstream Candida infections and for guidance in managing neutropenic patients.
Pharmacists are invaluable due to the numerous drug interactions associated with antifungal drugs, particularly the triazoles. Exercise caution when concurrently administering warfarin, rifampin, antiepileptic drugs, and sulfonylureas.
OPERATIONS/ADDITIONAL INTERVENTIONS
A surgical consultation is necessary to drain fluid collections infected with Candida species and to manage candidal endocarditis.
INPATIENT CONSIDERATIONS
Criteria for Admission
Patients suspected with candidemia should be hospitalized and administered empiric antifungal medication.
CONTINUING MANAGEMENT POST-TREATMENT GUIDELINES
Patient Surveillance
QT prolongation must be monitored via ECGs in patients administered triazoles (e.g., fluconazole, voriconazole).
• The pharmacy must evaluate potential drug interactions while administering antifungal medicines, particularly triazoles.
• Conduct daily blood cultures in patients with candidemia to confirm sterilization.
• Ophthalmology should evaluate all patients with candidemia for endophthalmitis.
OUTLOOK
Mortality progressively rises in patients with candidemia who have a delay in antifungal treatment. For instance, individuals treated three or more days after confirmed candidemia exhibit mortality rates above 40%.
COMPLICATIONS • Renal failure • Esophageal perforation • Endocarditis • Endophthalmitis • Meningitis • Peritonitis and adhesions • Pericarditis • Abscess • Mortality
- Published on
Infectious Disease – Cat Scratch Disease
CAT-SCRATCH DISEASE (AND BARTONELLA INFECTIONS)
Cat-scratch disease is generally a self-limiting acute condition characterized by regional lymphadenopathy, fever, and systemic symptoms, resulting from Bartonella henselae infection. Other manifestations of B. henselae infection encompass fever of unknown origin, hepatosplenic granulomatous disease, neuroretinitis, and encephalopathy.
Other medically significant Bartonella species comprise: – Bartonella quintana, historically responsible for trench fever, linked with persistent bacteremia, endocarditis, and bacillary angiomatosis. – Bartonella bacilliformis, the etiological agent of Oroya fever.
Epidemiology
Occurrence
The prevalence of cat-scratch disease in the United States is roughly 10 cases per 100,000 person-years, with an estimated 24,000 cases identified annually.
Cat-scratch illness is prevalent globally. In temperate areas, it is seasonal, with the majority of cases occurring from August to January.
Cat-scratch illness manifests in immunocompetent individuals across all age groups, with 80% of cases occurring in those under 21 years old.
Most instances of cat-scratch sickness are self-resolving and linked to regional lymphadenopathy.
B. quintana is considered to be worldwide endemic.
B. bacilliformis infection is transmitted through sand fly bites and is exclusively found at altitudes exceeding 1 km in the Andes mountains.
FACTORS OF RISK
Cats serve as the primary hosts and reservoirs of B. henselae.
Most instances of cat-scratch disease can be directly associated with exposure to cats, particularly kittens or felines infested with fleas. Ninety percent of patients had a history of contact with cats.
- A prior history of cat scratch in 60% of cases.
• Incidences of B. quintana infection have been documented among homeless individuals and those from socioeconomically poor backgrounds. These circumstances render persons susceptible to Pediculus humanus (human body louse), a vector for B. quintana infection.
Patients with advanced HIV infection and other immunocompromised individuals are at elevated risk of
progressive chronic infections induced by B. quintana and B. henselae, encompassing bacillary angiomatosis (vascular lesions) and bacillary peliosis (cystic lesions).
COMPREHENSIVE PREVENTION
The risk of cat-scratch disease can be mitigated by minimizing interactions that could result in scratches, bites, or licks from cats or kittens.
The management of cat fleas may diminish the danger of transmission and may be beneficial in households with immunocompromised individuals.
PATHOPHYSIOLOGY • Bartonella species possess the ability for intracellular persistence and induce inflammation in affected organs.
The inflammatory response in cat-scratch disease leads to localized granuloma development.
ETIOLOGY • Bartonella species are meticulous gram-negative rod-shaped aerobic bacteria. • The predominant cause of cat-scratch disease is B. henselae.
• Additional medically significant Bartonella infections encompass
B. quintana and B. bacilliformis. Numerous additional Bartonella species have been linked to isolated instances of human illness.
FREQUENTLY CO-OCCURRING CONDITIONS
B. henselae and B. quintana induce a unique array of illnesses in HIV infection (see to the preceding section). Chronic infections may also arise in recipients of solid-organ transplants and individuals with hematological malignancies.
HISTORY OF DIAGNOSIS
The primary symptom of cat-scratch disease frequently manifests as a tiny erythematous papule or pustule at the scratch site, which endures for several weeks.
• Consequently, lymph nodes associated with the inoculation site become hypertrophied and sensitive.
Patients with cat-scratch disease may not consistently exhibit fever. Low-grade fever and malaise occur in 30% of patients.
Other indications of cat-scratch disease encompass prolonged fever, neuroretinitis (evidenced by diminished visual acuity or alterations in vision), and encephalopathy (characterized by abnormalities in mental status).
B. henselae bacteremia in individuals infected with HIV is linked to a gradual onset of lethargy, malaise, myalgia, weight loss, recurrent fevers of increasing duration and intensity, and occasionally, headaches. Hepatomegaly may be present.
Trench fever is the quintessential manifestation of B. quintana infection, and its natural progression in healthy individuals has been thoroughly documented. Incubation subsequent to inoculation
may extend from 3 to 38 days before to the typically abrupt emergence of chills and fevers. Afebrile infection represents the least prevalent variant. The accompanying symptoms and signs (e.g., headache, vertigo, retro-orbital pain, conjunctival infection) are all vague.
The physical morphology of bacillary angiomatosis is characterized by subcutaneous or dermal nodules and/or single or numerous dome-shaped papules that are skin-colored or red-to-purple, which may exhibit ulceration, serous or bloody exudate, and crusting. Visceral lesions can be notably striking, both in their quantity and the diversity of their macroscopic appearance.
Bacillary peliosis affects organs characterized by multiple blood-filled cystic formations, varying in size from microscopic to several millimeters.
PHYSICAL EXAM • Regional lymphadenopathy is the predominant physical manifestation in cat-scratch disease, occurring in lymph nodes that drain the inoculation site. • In numerous instances, a tiny granuloma or lesion may be identified at the site of inoculation.
Parinaud’s oculoglandular syndrome occurs in roughly 5% of individuals with cat-scratch disease, characterized by conjunctivitis, conjunctival granuloma, and preauricular lymphadenopathy.
Patients with visceral disease may exhibit hepatosplenomegaly.
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Initial Assessments
In the initial stages of the disease, the total white blood cell count may reveal mild leukocytosis and an elevated count of polymorphonuclear cells, with eosinophilia observed in 10–20% of individuals.
B. henselae and B. quintana can be isolated from blood using lysis-centrifugation blood cultures; however, both species have also been successfully isolated with the BACTEC blood culture method.
Serological assays for B. henselae are being standardized. Numerous commercial testing laboratories do an indirect fluorescence assay. Low positive titers (1:64–1:256) may indicate recent or past infection, whereas titers beyond 1:256 strongly suggest active infection (2).
Subsequent Actions & Unique Considerations
In instances of inconclusive serology, a repeat test after two weeks may aid in confirming a diagnosis.
Imaging
Ultrasound of swollen lymph nodes can assist in assessing other causes of lymphadenopathy, identifying early suppuration of the bubo, and guiding needle aspiration as necessary.
Diagnostic Procedures and Additional Methods
Excisional biopsy or fine needle aspiration is frequently conducted in instances of regional lymphadenopathy.
Pathological Observations
Pathological findings reveal nonspecific granuloma development in the afflicted lymph nodes. A positive Warthin–Starry stain or tissue PCR for Bartonella indicates the possibility of cat-scratch disease, albeit they are not consistently positive.
DIFFERENTIAL DIAGNOSIS • The diagnosis of cat-scratch illness in individuals exhibiting regional lymphadenopathy or a clinical condition characteristic of cat-scratch disease is indicated by the following:
- Interaction with a feline and the existence of a scratch or
main lesion - A confirmed serological assay for Bartonella
– Distinct histopathologic features (the presence of many microabscesses or granulomas in a lymph node biopsy material)
– Exclusion of other recognizable etiologies, particularly mycobacterial infections and suppurative adenitis
INITIAL THERAPY MEDICATION
The literature contains numerous contradicting assertions regarding the role and selection of antibiotics for cat-scratch illness (3).
• While the condition typically resolves spontaneously, antibiotics may expedite recovery and are hence frequently employed in the treatment of cat-scratch disease.
Azithromycin (500 mg orally as a single dose, followed by 250 mg once day for the subsequent four days) is applicable for adults.
The management of cat-scratch neuroretinitis remains contentious; nonetheless, retrospective studies indicate that the combination of doxycycline and rifampin is linked to a more expedited alleviation of symptoms (4).
For bacillary angiomatosis limited to the skin, an oral regimen of erythromycin 500 mg administered four times daily or doxycycline 100 mg taken twice daily for a duration of 8–12 weeks is advised. Lesions typically start to diminish after a week, but generally require a somewhat longer duration to fully resolve and may result in residual hyperpigmentation.
If unresolved by 12 weeks, therapy should be prolonged.
• A minimum of 4 weeks of treatment is required for bacteremia.
Prolonged treatment (2–3 months) is warranted in an HIV-infected patient with chronic or recurrent fever, particularly in the context of endocarditis.
Second Line
Additional oral medications considered useful against cat-scratch disease include rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
• In the event of suppuration, aspiration should be contemplated to alleviate pain and expedite recovery. Needle aspiration is typically favored over incision and drainage. Following the cleansing of the skin with an iodophor skin cleanser, aspiration can be performed by inserting an 18- or 19-gauge needle tangentially through healthy skin near the base of the node. Reaspiration may be required seldom.
In endocarditis, hemodynamic factors may necessitate valve replacement (see to chapters in Section II on endocarditis).
CONTINUING TREATMENT POST-CARE SUGGESTIONS
The lymphadenopathy associated with cat-scratch illness typically recovers spontaneously over several months.
• A single occurrence of cat-scratch sickness seems to provide enduring immunity. Occasionally, a reemergence of sinus tract drainage from the initially affected nodes may transpire. In cases of large adenopathy (>5 cm), chronic adenopathy may endure for 1 to 2 years.
• The resolution of fever in patients with bacteremia often occurs rapidly in non-HIV-infected individuals, however it may extend to several weeks in those infected with HIV. Typically, bacteremia becomes undetectable within a week of initiating medication, despite the potential continuation of fever.
DIET: Standard.
INFORMATION FOR PATIENTS
Patients must be informed about the transmission method and the possible dangers to immunocompromised others in the household who have comparable exposure to cats.
OUTLOOK
Simple cat-scratch illness has a favorable prognosis. Lymphadenopathy related to mild cat-scratch disease in immunocompetent persons heals within weeks to many months. Complications including retinitis, encephalopathy, or severe systemic disease manifest in 5–14% of instances.
COMPLICATIONS
• Encephalopathy typically manifests many weeks following the severe sickness. Seizures and status epilepticus may indicate encephalopathy but are self-limiting, with prompt recovery typically occurring within a few days. The cerebrospinal fluid is typically normal, although pleocytosis may arise. The etiology of the encephalopathy remains ambiguous, while direct infection, a toxin, and an autoimmune mechanism have been suggested as contributing factors.
Inflammatory responses to B. henselae infection in individuals with AIDS, absent of accompanying angiomatosis or peliosis, have been seen affecting the liver and spleen.
lymph nodes, cardiac organ, and bone marrow
CAT-SCRATCH DISEASE (AND BARTONELLA INFECTIONS)
Cat-scratch disease is generally a self-limiting acute condition characterized by regional lymphadenopathy, fever, and systemic symptoms, resulting from Bartonella henselae infection. Other manifestations of B. henselae infection encompass fever of unknown origin, hepatosplenic granulomatous disease, neuroretinitis, and encephalopathy.
Other medically significant Bartonella species comprise: – Bartonella quintana, historically responsible for trench fever, linked with persistent bacteremia, endocarditis, and bacillary angiomatosis. – Bartonella bacilliformis, the etiological agent of Oroya fever.
Epidemiology
Occurrence
The prevalence of cat-scratch disease in the United States is roughly 10 cases per 100,000 person-years, with an estimated 24,000 cases identified annually.
Cat-scratch illness is prevalent globally. In temperate areas, it is seasonal, with the majority of cases occurring from August to January.
Cat-scratch illness manifests in immunocompetent individuals across all age groups, with 80% of cases occurring in those under 21 years old.
Most instances of cat-scratch sickness are self-resolving and linked to regional lymphadenopathy.
B. quintana is considered to be worldwide endemic.
B. bacilliformis infection is transmitted through sand fly bites and is exclusively found at altitudes exceeding 1 km in the Andes mountains.
FACTORS OF RISK
Cats serve as the primary hosts and reservoirs of B. henselae.
Most instances of cat-scratch disease can be directly associated with exposure to cats, particularly kittens or felines infested with fleas. Ninety percent of patients had a history of contact with cats.
- A prior history of cat scratch in 60% of cases.
• Incidences of B. quintana infection have been documented among homeless individuals and those from socioeconomically poor backgrounds. These circumstances render persons susceptible to Pediculus humanus (human body louse), a vector for B. quintana infection.
Patients with advanced HIV infection and other immunocompromised individuals are at elevated risk of
progressive chronic infections induced by B. quintana and B. henselae, encompassing bacillary angiomatosis (vascular lesions) and bacillary peliosis (cystic lesions).
COMPREHENSIVE PREVENTION
The risk of cat-scratch disease can be mitigated by minimizing interactions that could result in scratches, bites, or licks from cats or kittens.
The management of cat fleas may diminish the danger of transmission and may be beneficial in households with immunocompromised individuals.
PATHOPHYSIOLOGY • Bartonella species possess the ability for intracellular persistence and induce inflammation in affected organs.
The inflammatory response in cat-scratch disease leads to localized granuloma development.
ETIOLOGY • Bartonella species are meticulous gram-negative rod-shaped aerobic bacteria. • The predominant cause of cat-scratch disease is B. henselae.
• Additional medically significant Bartonella infections encompass
B. quintana and B. bacilliformis. Numerous additional Bartonella species have been linked to isolated instances of human illness.
FREQUENTLY CO-OCCURRING CONDITIONS
B. henselae and B. quintana induce a unique array of illnesses in HIV infection (see to the preceding section). Chronic infections may also arise in recipients of solid-organ transplants and individuals with hematological malignancies.
HISTORY OF DIAGNOSIS
The primary symptom of cat-scratch disease frequently manifests as a tiny erythematous papule or pustule at the scratch site, which endures for several weeks.
• Consequently, lymph nodes associated with the inoculation site become hypertrophied and sensitive.
Patients with cat-scratch disease may not consistently exhibit fever. Low-grade fever and malaise occur in 30% of patients.
Other indications of cat-scratch disease encompass prolonged fever, neuroretinitis (evidenced by diminished visual acuity or alterations in vision), and encephalopathy (characterized by abnormalities in mental status).
B. henselae bacteremia in individuals infected with HIV is linked to a gradual onset of lethargy, malaise, myalgia, weight loss, recurrent fevers of increasing duration and intensity, and occasionally, headaches. Hepatomegaly may be present.
Trench fever is the quintessential manifestation of B. quintana infection, and its natural progression in healthy individuals has been thoroughly documented. Incubation subsequent to inoculation
may extend from 3 to 38 days before to the typically abrupt emergence of chills and fevers. Afebrile infection represents the least prevalent variant. The accompanying symptoms and signs (e.g., headache, vertigo, retro-orbital pain, conjunctival infection) are all vague.
The physical morphology of bacillary angiomatosis is characterized by subcutaneous or dermal nodules and/or single or numerous dome-shaped papules that are skin-colored or red-to-purple, which may exhibit ulceration, serous or bloody exudate, and crusting. Visceral lesions can be notably striking, both in their quantity and the diversity of their macroscopic appearance.
Bacillary peliosis affects organs characterized by multiple blood-filled cystic formations, varying in size from microscopic to several millimeters.
PHYSICAL EXAM • Regional lymphadenopathy is the predominant physical manifestation in cat-scratch disease, occurring in lymph nodes that drain the inoculation site. • In numerous instances, a tiny granuloma or lesion may be identified at the site of inoculation.
Parinaud’s oculoglandular syndrome occurs in roughly 5% of individuals with cat-scratch disease, characterized by conjunctivitis, conjunctival granuloma, and preauricular lymphadenopathy.
Patients with visceral disease may exhibit hepatosplenomegaly.
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Initial Assessments
In the initial stages of the disease, the total white blood cell count may reveal mild leukocytosis and an elevated count of polymorphonuclear cells, with eosinophilia observed in 10–20% of individuals.
B. henselae and B. quintana can be isolated from blood using lysis-centrifugation blood cultures; however, both species have also been successfully isolated with the BACTEC blood culture method.
Serological assays for B. henselae are being standardized. Numerous commercial testing laboratories do an indirect fluorescence assay. Low positive titers (1:64–1:256) may indicate recent or past infection, whereas titers beyond 1:256 strongly suggest active infection (2).
Subsequent Actions & Unique Considerations
In instances of inconclusive serology, a repeat test after two weeks may aid in confirming a diagnosis.
Imaging
Ultrasound of swollen lymph nodes can assist in assessing other causes of lymphadenopathy, identifying early suppuration of the bubo, and guiding needle aspiration as necessary.
Diagnostic Procedures and Additional Methods
Excisional biopsy or fine needle aspiration is frequently conducted in instances of regional lymphadenopathy.
Pathological Observations
Pathological findings reveal nonspecific granuloma development in the afflicted lymph nodes. A positive Warthin–Starry stain or tissue PCR for Bartonella indicates the possibility of cat-scratch disease, albeit they are not consistently positive.
DIFFERENTIAL DIAGNOSIS • The diagnosis of cat-scratch illness in individuals exhibiting regional lymphadenopathy or a clinical condition characteristic of cat-scratch disease is indicated by the following:
- Interaction with a feline and the existence of a scratch or
main lesion - A confirmed serological assay for Bartonella
– Distinct histopathologic features (the presence of many microabscesses or granulomas in a lymph node biopsy material)
– Exclusion of other recognizable etiologies, particularly mycobacterial infections and suppurative adenitis
INITIAL THERAPY MEDICATION
The literature contains numerous contradicting assertions regarding the role and selection of antibiotics for cat-scratch illness (3).
• While the condition typically resolves spontaneously, antibiotics may expedite recovery and are hence frequently employed in the treatment of cat-scratch disease.
Azithromycin (500 mg orally as a single dose, followed by 250 mg once day for the subsequent four days) is applicable for adults.
The management of cat-scratch neuroretinitis remains contentious; nonetheless, retrospective studies indicate that the combination of doxycycline and rifampin is linked to a more expedited alleviation of symptoms (4).
For bacillary angiomatosis limited to the skin, an oral regimen of erythromycin 500 mg administered four times daily or doxycycline 100 mg taken twice daily for a duration of 8–12 weeks is advised. Lesions typically start to diminish after a week, but generally require a somewhat longer duration to fully resolve and may result in residual hyperpigmentation.
If unresolved by 12 weeks, therapy should be prolonged.
• A minimum of 4 weeks of treatment is required for bacteremia.
Prolonged treatment (2–3 months) is warranted in an HIV-infected patient with chronic or recurrent fever, particularly in the context of endocarditis.
Second Line
Additional oral medications considered useful against cat-scratch disease include rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
• In the event of suppuration, aspiration should be contemplated to alleviate pain and expedite recovery. Needle aspiration is typically favored over incision and drainage. Following the cleansing of the skin with an iodophor skin cleanser, aspiration can be performed by inserting an 18- or 19-gauge needle tangentially through healthy skin near the base of the node. Reaspiration may be required seldom.
In endocarditis, hemodynamic factors may necessitate valve replacement (see to chapters in Section II on endocarditis).
CONTINUING TREATMENT POST-CARE SUGGESTIONS
The lymphadenopathy associated with cat-scratch illness typically recovers spontaneously over several months.
• A single occurrence of cat-scratch sickness seems to provide enduring immunity. Occasionally, a reemergence of sinus tract drainage from the initially affected nodes may transpire. In cases of large adenopathy (>5 cm), chronic adenopathy may endure for 1 to 2 years.
• The resolution of fever in patients with bacteremia often occurs rapidly in non-HIV-infected individuals, however it may extend to several weeks in those infected with HIV. Typically, bacteremia becomes undetectable within a week of initiating medication, despite the potential continuation of fever.
DIET: Standard.
INFORMATION FOR PATIENTS
Patients must be informed about the transmission method and the possible dangers to immunocompromised others in the household who have comparable exposure to cats.
OUTLOOK
Simple cat-scratch illness has a favorable prognosis. Lymphadenopathy related to mild cat-scratch disease in immunocompetent persons heals within weeks to many months. Complications including retinitis, encephalopathy, or severe systemic disease manifest in 5–14% of instances.
COMPLICATIONS
• Encephalopathy typically manifests many weeks following the severe sickness. Seizures and status epilepticus may indicate encephalopathy but are self-limiting, with prompt recovery typically occurring within a few days. The cerebrospinal fluid is typically normal, although pleocytosis may arise. The etiology of the encephalopathy remains ambiguous, while direct infection, a toxin, and an autoimmune mechanism have been suggested as contributing factors.
Inflammatory responses to B. henselae infection in individuals with AIDS, absent of accompanying angiomatosis or peliosis, have been seen affecting the liver and spleen.
lymph nodes, cardiac organ, and bone marrow
- Published on
nfectious Disease - CERVICITIS
FUNDAMENTAL DESCRIPTION
Sexually transmitted infection characterized by inflammation of the endocervix and/or ectocervix.
Epidemiology
Prevalence • Common among sexually active adolescent females under 20 years of age • Also observed in young adults aged 20 to 24 years
• A prospective cohort study in the United States with 14,322 young adults aged 18 to 26 years:
The overall prevalence of chlamydial infection was 4.2%.
Women (4.7%) exhibited a higher infection rate than men (3.7%). The incidence was greatest among Black women.
– The overall prevalence of gonorrhea was 0.4%.
The prevalence of coinfection with chlamydial and gonococcal infections was 0.03%.
RISK FACTORS • Recent sexual partner during the last 3 months • Multiple sexual partners within the past 6 months • Sexual partner with several other partners • Irregular use of barrier contraception
GENERAL PREVENTION • Implementation of safe sexual practices • Assessment and treatment of sexual partners
• In instances where medical evaluation, counseling, and partner treatment are unfeasible, patient-delivered therapy serves as an alternative.
• Initiate presumptive treatment when the prevalence of Chlamydia trachomatis or Neisseria gonorrhoeae is elevated, or when adherence to follow-up appointments is considered improbable.
Annual chlamydial screening is advised for all sexually active women aged 25 years or younger, as well as for older women with risk factors, such as having a new or many sex partners.
ETIOLOGY
• Chlamydia trachomatis • Neisseria gonorrhoeae • Mycoplasma hominis, Ureaplasma urealyticum
• Mycoplasma genitalium • Herpes simplex virus • In most instances, no organism is identified • Vaginal infections caused by Trichomonas vaginalis or Candida albicans may extend to the ectocervix • Cytomegalovirus is seldom a causative agent
DIAGNOSTIC HISTORY
• Often asymptomatic • Abnormal vaginal discharge or bleeding, especially post-coitus • Dysuria or increased urinary frequency • Dyspareunia
PHYSICAL EXAMINATION • Presence of yellow exudate in the endocervical canal or on an endocervical swab specimen • Cervical friability observed
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Preliminary laboratory examinations • cultivation of cervical discharge, encompassing cultivation for N. gonorrhoeae utilizing modified Thayer–Martin media.
• Gram staining
Cytological analysis of endocervical mucus specimens:
– The identification of gram-negative, intracellular diplococci in endocervical mucus is strongly indicative of gonococcal infection. It exhibits just 50% sensitivity in mucopurulent cervicitis, but it demonstrates 95% sensitivity in gonococcal urethritis. Microscopic analysis of ectocervical fluid specimens utilizing standard wet-mount saline and potassium hydroxide. Leukorrhea (>10 WBC per high power field in microscopic analysis of vaginal fluid) is linked to chlamydial and gonococcal infections of the cervix.
Nucleic acid amplification testing for Neisseria gonorrhoeae and Chlamydia trachomatis. This can be conducted on an endocervical sample, vaginal swab specimen, or urine.
• In the presence of cervical ulcers or necrotic lesions, conduct testing for genital herpes using PCR, DFA, virus culture, or type-specific serology.
• Women diagnosed with cervicitis should undergo assessment for bacterial vaginosis, trichomoniasis, and pelvic inflammatory disease.
• Caution: Clean the ectocervix with a swab before to collecting the endocervical mucus samples.
Subsequent Actions & Unique
Considerations • The management of sexual partners should be tailored to the diagnosed or suspected infection.
Patients and their sexual partners must refrain from sexual intercourse until therapy is concluded, specifically 7 days following a single-dose regimen or upon completion of a 7-day regimen, to prevent re-infection.
• In HIV-positive women, the management of cervicitis diminishes viral shedding and the likelihood of HIV transmission.
Pediatric Considerations
In pre-adolescent children, sexual abuse should be regarded as a potential source of chlamydial or gonococcal infection.
THERAPEUTIC PHARMACEUTICAL
Presumptive therapy is warranted when there is a significant incidence of C. trachomatis and N. gonorrhoeae in the local community, coupled with a low probability of patient adherence to follow-up appointments. It is advisable to await test findings prior to commencing treatment if the prevalence of C. trachomatis and N. gonorrhoeae is low and adherence to follow-up visits is probable.
Initial Line
• Chlamydia infection:
– Azithromycin 1 g orally, single dosage, or – Doxycycline 100 mg orally twice day for 7 days
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage.
• Targeted therapy for alternative etiologies of cervicitis is warranted.
Second Line •
Chlamydial infection: – Ofloxacin 300 mg orally twice day for 7 days Levofloxacin 500 mg orally once daily for seven days
Erythromycin base 500 mg orally four times daily for seven days
• Gonococcal infection: – Administer Cefixime 400 mg orally as a single dosage.
Cefpodoxime 400 mg orally, one administration
The bactericidal level of oral cephalosporins is neither as elevated nor as prolonged as that of ceftriaxone.
– Fluoroquinolones are contraindicated due to rising incidence of gonococcal resistance.
- Spectinomycin 2 g intramuscularly, single administration
Spectinomycin exhibits limited effectiveness in gonococcal pharyngitis.
– It is important to note that Spectinomycin is not currently produced in the United States.
– A solitary 2 g oral administration of azithromycin is efficacious for uncomplicated urogenital gonococcal infection. It is inadvisable due to gastrointestinal intolerance and expense. Moreover, prolonged low concentrations of the medicine may facilitate the development of resistance.
Considerations for Pregnancy:
Primary Line
• Chlamydial infection: – Azithromycin 1 g orally, single dosage ,or – Amoxicillin 500 mg orally three times daily for 7 days
• Theoretically, amoxicillin may lead to a chronic chlamydial infection instead of achieving a microbiological cure. The clinical evidence available are inadequate to substantiate this worry.
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage. Second Line.
• Chlamydial infection: – Erythromycin base 500 mg orally four times daily for 7 days
Erythromycin base 250 mg orally four times daily for 14 days
Erythromycin ethylsuccinate 800 mg orally four times day for seven days.
Erythromycin ethylsuccinate 400 mg orally four times day for 14 days:
Administer a reduced dosage in cases of gastrointestinal intolerance; fluoroquinolones and tetracyclines are contraindicated.
Erythromycin estolate is contraindicated in pregnancy due to its potential hepatotoxic effects.
• Gonococcal infection: Alternative cephalosporin or spectinomycin
CONTINUING TREATMENT POST-CARE SUGGESTIONS
• A test-of-cure for chlamydial infection is advised solely in the following circumstances:
– If therapy adherence is uncertain – If symptoms continue – If re-infection is suspected – During pregnancy • Follow-up testing should not occur immediately after clinical remission. Non-culture testing for C. trachomatis conducted within three weeks post-successful therapy may yield false-positive results because to the persistent excretion of nonviable organisms.
Patients with simple gonorrhea who have received adequate treatment do not require a test of cure. Patients exhibiting chronic symptoms should undergo culture evaluation for N. gonorrhoeae, and any isolated gonococci must be assessed for antibiotic susceptibility.
• In cases of persistent cervicitis, consider the following: – Re-infection (treat partner) – Bacterial vaginosis • Repeat screening should be contemplated within the initial three to four months post-therapy completion is recommended due to the elevated risk of re-infection, particularly among sexually active teens.
Patient Education: Recommend safe sexual practices.
COMPLICATIONS • Pelvic inflammatory illness • Ectopic pregnancy • Infertility • Chorioamnionitis • Premature rupture of membranes • Puerperal infections
FUNDAMENTAL DESCRIPTION
Sexually transmitted infection characterized by inflammation of the endocervix and/or ectocervix.
Epidemiology
Prevalence • Common among sexually active adolescent females under 20 years of age • Also observed in young adults aged 20 to 24 years
• A prospective cohort study in the United States with 14,322 young adults aged 18 to 26 years:
The overall prevalence of chlamydial infection was 4.2%.
Women (4.7%) exhibited a higher infection rate than men (3.7%). The incidence was greatest among Black women.
– The overall prevalence of gonorrhea was 0.4%.
The prevalence of coinfection with chlamydial and gonococcal infections was 0.03%.
RISK FACTORS • Recent sexual partner during the last 3 months • Multiple sexual partners within the past 6 months • Sexual partner with several other partners • Irregular use of barrier contraception
GENERAL PREVENTION • Implementation of safe sexual practices • Assessment and treatment of sexual partners
• In instances where medical evaluation, counseling, and partner treatment are unfeasible, patient-delivered therapy serves as an alternative.
• Initiate presumptive treatment when the prevalence of Chlamydia trachomatis or Neisseria gonorrhoeae is elevated, or when adherence to follow-up appointments is considered improbable.
Annual chlamydial screening is advised for all sexually active women aged 25 years or younger, as well as for older women with risk factors, such as having a new or many sex partners.
ETIOLOGY
• Chlamydia trachomatis • Neisseria gonorrhoeae • Mycoplasma hominis, Ureaplasma urealyticum
• Mycoplasma genitalium • Herpes simplex virus • In most instances, no organism is identified • Vaginal infections caused by Trichomonas vaginalis or Candida albicans may extend to the ectocervix • Cytomegalovirus is seldom a causative agent
DIAGNOSTIC HISTORY
• Often asymptomatic • Abnormal vaginal discharge or bleeding, especially post-coitus • Dysuria or increased urinary frequency • Dyspareunia
PHYSICAL EXAMINATION • Presence of yellow exudate in the endocervical canal or on an endocervical swab specimen • Cervical friability observed
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory Preliminary laboratory examinations • cultivation of cervical discharge, encompassing cultivation for N. gonorrhoeae utilizing modified Thayer–Martin media.
• Gram staining
Cytological analysis of endocervical mucus specimens:
– The identification of gram-negative, intracellular diplococci in endocervical mucus is strongly indicative of gonococcal infection. It exhibits just 50% sensitivity in mucopurulent cervicitis, but it demonstrates 95% sensitivity in gonococcal urethritis. Microscopic analysis of ectocervical fluid specimens utilizing standard wet-mount saline and potassium hydroxide. Leukorrhea (>10 WBC per high power field in microscopic analysis of vaginal fluid) is linked to chlamydial and gonococcal infections of the cervix.
Nucleic acid amplification testing for Neisseria gonorrhoeae and Chlamydia trachomatis. This can be conducted on an endocervical sample, vaginal swab specimen, or urine.
• In the presence of cervical ulcers or necrotic lesions, conduct testing for genital herpes using PCR, DFA, virus culture, or type-specific serology.
• Women diagnosed with cervicitis should undergo assessment for bacterial vaginosis, trichomoniasis, and pelvic inflammatory disease.
• Caution: Clean the ectocervix with a swab before to collecting the endocervical mucus samples.
Subsequent Actions & Unique
Considerations • The management of sexual partners should be tailored to the diagnosed or suspected infection.
Patients and their sexual partners must refrain from sexual intercourse until therapy is concluded, specifically 7 days following a single-dose regimen or upon completion of a 7-day regimen, to prevent re-infection.
• In HIV-positive women, the management of cervicitis diminishes viral shedding and the likelihood of HIV transmission.
Pediatric Considerations
In pre-adolescent children, sexual abuse should be regarded as a potential source of chlamydial or gonococcal infection.
THERAPEUTIC PHARMACEUTICAL
Presumptive therapy is warranted when there is a significant incidence of C. trachomatis and N. gonorrhoeae in the local community, coupled with a low probability of patient adherence to follow-up appointments. It is advisable to await test findings prior to commencing treatment if the prevalence of C. trachomatis and N. gonorrhoeae is low and adherence to follow-up visits is probable.
Initial Line
• Chlamydia infection:
– Azithromycin 1 g orally, single dosage, or – Doxycycline 100 mg orally twice day for 7 days
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage.
• Targeted therapy for alternative etiologies of cervicitis is warranted.
Second Line •
Chlamydial infection: – Ofloxacin 300 mg orally twice day for 7 days Levofloxacin 500 mg orally once daily for seven days
Erythromycin base 500 mg orally four times daily for seven days
• Gonococcal infection: – Administer Cefixime 400 mg orally as a single dosage.
Cefpodoxime 400 mg orally, one administration
The bactericidal level of oral cephalosporins is neither as elevated nor as prolonged as that of ceftriaxone.
– Fluoroquinolones are contraindicated due to rising incidence of gonococcal resistance.
- Spectinomycin 2 g intramuscularly, single administration
Spectinomycin exhibits limited effectiveness in gonococcal pharyngitis.
– It is important to note that Spectinomycin is not currently produced in the United States.
– A solitary 2 g oral administration of azithromycin is efficacious for uncomplicated urogenital gonococcal infection. It is inadvisable due to gastrointestinal intolerance and expense. Moreover, prolonged low concentrations of the medicine may facilitate the development of resistance.
Considerations for Pregnancy:
Primary Line
• Chlamydial infection: – Azithromycin 1 g orally, single dosage ,or – Amoxicillin 500 mg orally three times daily for 7 days
• Theoretically, amoxicillin may lead to a chronic chlamydial infection instead of achieving a microbiological cure. The clinical evidence available are inadequate to substantiate this worry.
• Gonococcal infection: Administer 250 mg of Ceftriaxone intramuscularly as a single dosage. Second Line.
• Chlamydial infection: – Erythromycin base 500 mg orally four times daily for 7 days
Erythromycin base 250 mg orally four times daily for 14 days
Erythromycin ethylsuccinate 800 mg orally four times day for seven days.
Erythromycin ethylsuccinate 400 mg orally four times day for 14 days:
Administer a reduced dosage in cases of gastrointestinal intolerance; fluoroquinolones and tetracyclines are contraindicated.
Erythromycin estolate is contraindicated in pregnancy due to its potential hepatotoxic effects.
• Gonococcal infection: Alternative cephalosporin or spectinomycin
CONTINUING TREATMENT POST-CARE SUGGESTIONS
• A test-of-cure for chlamydial infection is advised solely in the following circumstances:
– If therapy adherence is uncertain – If symptoms continue – If re-infection is suspected – During pregnancy • Follow-up testing should not occur immediately after clinical remission. Non-culture testing for C. trachomatis conducted within three weeks post-successful therapy may yield false-positive results because to the persistent excretion of nonviable organisms.
Patients with simple gonorrhea who have received adequate treatment do not require a test of cure. Patients exhibiting chronic symptoms should undergo culture evaluation for N. gonorrhoeae, and any isolated gonococci must be assessed for antibiotic susceptibility.
• In cases of persistent cervicitis, consider the following: – Re-infection (treat partner) – Bacterial vaginosis • Repeat screening should be contemplated within the initial three to four months post-therapy completion is recommended due to the elevated risk of re-infection, particularly among sexually active teens.
Patient Education: Recommend safe sexual practices.
COMPLICATIONS • Pelvic inflammatory illness • Ectopic pregnancy • Infertility • Chorioamnionitis • Premature rupture of membranes • Puerperal infections
- Published on
Infectious Disease- Coccidioiddomycosis
COCCIDIOIDDOMYCOSIS
ESSENTIALS DESCRIPTION
The dimorphic fungus Coccidioides immitis is the cause of pulmonary and/or extrapulmonary infections caused by coccidioidomycosis.
The incidence of epidemiology • There are roughly 91 instances of coccidioidomycosis for every 100,000 people in the United States. throughout addition to Mexico and Central and South America, C. immitis is endemic throughout the southwestern United States (primarily California, Arizona, and Texas). More and more cases are being identified outside of the endemic areas (travelers or reactivations). • The number of patients grows sharply on a periodic basis.
RISK ELEMENTS
Due to the possibility of late recrudescence of latent infection, patients with immunosuppressive diseases or treatments, such as AIDS, solid-organ transplantation, or lymphoma, should be mindful of even remote exposure to endemic areas. Patients with AIDS who have CD4 counts below 250 cells/mm3 are at a higher risk of developing coccidioidomycosis. Although the precise amount of steroids that indicates an elevated risk has not been determined, patients undergoing immunosuppressive and glucocorticoid therapy are more susceptible to coccidioidomycosis.
PATHOPHYSIOLOGY
A progressive pneumonia or chronic lung infection may occur if the acute pulmonary infection does not go away
• Antifungal treatment should be administered to patients having a history of coccidioidomycosis at the time of engraftment, regardless of whether they are currently infected, according to experience with organ transplantation. Even asymptomatic seropositive transplant recipients should get antifungal treatment during acute rejection episodes.
ETIOLOGY • C. immitis is a soil-dwelling fungus that thrives at 27°C, while 30°C is the ideal temperature for its growth.
COMMON CONNECTED CIRCUMSTANCES
Usually referred to as "Valley fever," this condition can affect immunocompetent persons and more invasively affect immunocompromised patients. History of Diagnosis • One to three weeks following exposure, symptoms appear. A lower respiratory infection with systemic symptoms like the following is the usual presentation: Sputum production, fever, coughing, chest pain, anorexia, and arthritis Sweating; weakness; the development of erythema nodosum or erythema multiforme. • Asymptomatic residual illness in the lungs, typically nodules or thin-walled cavities, affects approximately 5% of infected individuals. • Approximately one out of every 200 individuals infected with C. immitis develops symptomatic extrapulmonary illness. The skin, soft tissues, bone and joints, and meninges are the typical locations. • If immunity is compromised by medicine or illness, sickness outside the lungs may manifest considerably later than the typical one-year period following the original infection. • Although there are many different types of skin involvement, wart-like nodules are the most prevalent. • More than 90% of individuals with joint involvement have unilateral joint lesions.
MEDICAL EXAMINATION
The skin and nerve system should receive particular attention for any involvement. • Since coccidioidal lesions are frequently focused and generate localized symptoms like discomfort, swelling, or ulceration, a thorough evaluation of symptoms and physical examination are usually sufficient to identify the presence of an extrapulmonary infection.
Diagnostic Examination and Interpretation Laboratory
• When a lung nodule is removed due to probable cancer in endemic locations, a history of C. immitis infection is often identified. • Accurate travel history collection is essential for timely detection of coccidioidal illness in patients who are not in endemic areas. Culture, serologic testing, and a positive coccidioidal skin test are the cornerstones of diagnosis. Experienced labs are the ideal places to do serologic testing. In 75% of patients with initial infections, serum IgM antibodies can be momentarily identified. If the illness goes away, the IgG antibody, which is present later, normally goes away in a few months. Seldom do serologic testing result in false positives. Nearly all patients with primary infections have positive skin-test reactions to coccidioidal antigens shortly after symptoms appear, and cross-reactions with other illnesses are uncommon. Patients with primary infections frequently do not have cultures, despite the fact that they are frequently used to diagnosis coccidioidomycosis in patients with disseminated infections. The basilar meninges are typically affected by meningitis. When the CSF fluid is examined, it reveals mononuclear pleocytosis, low glucose, and high protein levels.
Imagining
Hilar adenopathy, a pleural effusion, and infiltrates are possible radiographic findings of the chest. Diabetes, immunosuppressive illnesses or treatments, and late-stage pregnancy are associated ailments that are especially significant risk factors. Lung cancer and other widespread fungal infections are examples of differential diagnosis. First Line of Treatment Medication • Because controlled comparisons between antifungal and placebo regimens have not been conducted, the role of antifungal medication in individuals with mild or severe early infection symptoms is not well established
• Therapy might speed up the resolution of symptoms. Therefore, doctors should determine if a patient's situation calls for treatment with the available oral antifungal drugs on a case-by-case basis
• If treatment is started, 400 mg/d of fluconazole and 200 mg twice daily of itraconazole are appropriate dosing. Generally speaking, recommended therapy courses last three to six months. • The following are some factors that should be considered in favor of therapy: A negative skin test; conditions indicating a high fungal inoculum; and concurrent noncoccidioidal disease Increased host sensitivity, incapacity to function, elevated antibody titers, and infiltrations involving more than half of a lung - Severe night sweats that last more than three weeks - Weight loss of more than 10% Silar adenopathy that is noticeable or chronic; symptoms that last longer than two months
• Prolonged chemotherapy is always recommended for individuals with disseminated illness. • During chemotherapy, pulmonary resection can be used to treat severe hemoptysis or cavities that burst or expand. In order to empty empyemas, seal persistent bronchopleural fistulas, or enlarge lungs that are constrained by lingering illness, surgery may also be necessary. • The preferred medications for treating meningeal illness are fluconazole and itraconazole. • The fact that azole therapy is well tolerated, does not have the toxic effects of amphotericin B, and does not require administration into the cerebrospinal fluid may represent significant advantages in patients with an otherwise fatal illness, even if C. immitis infection cannot be cured and lifelong suppression is necessary. Line Two Chemotherapy is nearly usually recommended once the illness has progressed outside of the lungs. Patients who do not respond to azole treatment are treated with amphotericin B.
PERMANENT CARE FOLLOW-UP ADVICE
• Residual sequelae, many of which have minimal long-term effects, are caused by 5–10% of infections. • The serologic response to C. immitis is typically at least qualitatively intact in those who are more susceptible to infection. The doctor should be aware of the probability of this diagnosis if the patient has a history of travel or residency in endemic areas. A postponed diagnosis can be avoided with routine serologic testing. • Ninety percent of meningitis patients die within a year if treatment is not received, thus early detection is crucial. • Some individuals develop chronic lung disease as a result of their acute pneumonia, which never goes away. This group is disproportionately overrepresented among individuals with diabetes and those with weakened immune systems.
COMPLICATIONS
• Immunocompromised people are more susceptible to the disease, especially if they have extrapulmonary coccidioidal disease. The first year following an organ transplant is the time when patients are most vulnerable to infection. • Meningitis may manifest clinically practically simultaneously with the initial infection and typically develops 6 months after it. Typically, there are no symptoms of meningeal irritation that are typical with bacterial meningitis. The headache is the most typical symptom. There may be focal neurologic problems, fever, weakness, disorientation, sluggishness, seizures, aberrant behavior, stiff neck, diplopia, ataxia, and vomiting.
COCCIDIOIDDOMYCOSIS
ESSENTIALS DESCRIPTION
The dimorphic fungus Coccidioides immitis is the cause of pulmonary and/or extrapulmonary infections caused by coccidioidomycosis.
The incidence of epidemiology • There are roughly 91 instances of coccidioidomycosis for every 100,000 people in the United States. throughout addition to Mexico and Central and South America, C. immitis is endemic throughout the southwestern United States (primarily California, Arizona, and Texas). More and more cases are being identified outside of the endemic areas (travelers or reactivations). • The number of patients grows sharply on a periodic basis.
RISK ELEMENTS
Due to the possibility of late recrudescence of latent infection, patients with immunosuppressive diseases or treatments, such as AIDS, solid-organ transplantation, or lymphoma, should be mindful of even remote exposure to endemic areas. Patients with AIDS who have CD4 counts below 250 cells/mm3 are at a higher risk of developing coccidioidomycosis. Although the precise amount of steroids that indicates an elevated risk has not been determined, patients undergoing immunosuppressive and glucocorticoid therapy are more susceptible to coccidioidomycosis.
PATHOPHYSIOLOGY
A progressive pneumonia or chronic lung infection may occur if the acute pulmonary infection does not go away
• Antifungal treatment should be administered to patients having a history of coccidioidomycosis at the time of engraftment, regardless of whether they are currently infected, according to experience with organ transplantation. Even asymptomatic seropositive transplant recipients should get antifungal treatment during acute rejection episodes.
ETIOLOGY • C. immitis is a soil-dwelling fungus that thrives at 27°C, while 30°C is the ideal temperature for its growth.
COMMON CONNECTED CIRCUMSTANCES
Usually referred to as "Valley fever," this condition can affect immunocompetent persons and more invasively affect immunocompromised patients. History of Diagnosis • One to three weeks following exposure, symptoms appear. A lower respiratory infection with systemic symptoms like the following is the usual presentation: Sputum production, fever, coughing, chest pain, anorexia, and arthritis Sweating; weakness; the development of erythema nodosum or erythema multiforme. • Asymptomatic residual illness in the lungs, typically nodules or thin-walled cavities, affects approximately 5% of infected individuals. • Approximately one out of every 200 individuals infected with C. immitis develops symptomatic extrapulmonary illness. The skin, soft tissues, bone and joints, and meninges are the typical locations. • If immunity is compromised by medicine or illness, sickness outside the lungs may manifest considerably later than the typical one-year period following the original infection. • Although there are many different types of skin involvement, wart-like nodules are the most prevalent. • More than 90% of individuals with joint involvement have unilateral joint lesions.
MEDICAL EXAMINATION
The skin and nerve system should receive particular attention for any involvement. • Since coccidioidal lesions are frequently focused and generate localized symptoms like discomfort, swelling, or ulceration, a thorough evaluation of symptoms and physical examination are usually sufficient to identify the presence of an extrapulmonary infection.
Diagnostic Examination and Interpretation Laboratory
• When a lung nodule is removed due to probable cancer in endemic locations, a history of C. immitis infection is often identified. • Accurate travel history collection is essential for timely detection of coccidioidal illness in patients who are not in endemic areas. Culture, serologic testing, and a positive coccidioidal skin test are the cornerstones of diagnosis. Experienced labs are the ideal places to do serologic testing. In 75% of patients with initial infections, serum IgM antibodies can be momentarily identified. If the illness goes away, the IgG antibody, which is present later, normally goes away in a few months. Seldom do serologic testing result in false positives. Nearly all patients with primary infections have positive skin-test reactions to coccidioidal antigens shortly after symptoms appear, and cross-reactions with other illnesses are uncommon. Patients with primary infections frequently do not have cultures, despite the fact that they are frequently used to diagnosis coccidioidomycosis in patients with disseminated infections. The basilar meninges are typically affected by meningitis. When the CSF fluid is examined, it reveals mononuclear pleocytosis, low glucose, and high protein levels.
Imagining
Hilar adenopathy, a pleural effusion, and infiltrates are possible radiographic findings of the chest. Diabetes, immunosuppressive illnesses or treatments, and late-stage pregnancy are associated ailments that are especially significant risk factors. Lung cancer and other widespread fungal infections are examples of differential diagnosis. First Line of Treatment Medication • Because controlled comparisons between antifungal and placebo regimens have not been conducted, the role of antifungal medication in individuals with mild or severe early infection symptoms is not well established
• Therapy might speed up the resolution of symptoms. Therefore, doctors should determine if a patient's situation calls for treatment with the available oral antifungal drugs on a case-by-case basis
• If treatment is started, 400 mg/d of fluconazole and 200 mg twice daily of itraconazole are appropriate dosing. Generally speaking, recommended therapy courses last three to six months. • The following are some factors that should be considered in favor of therapy: A negative skin test; conditions indicating a high fungal inoculum; and concurrent noncoccidioidal disease Increased host sensitivity, incapacity to function, elevated antibody titers, and infiltrations involving more than half of a lung - Severe night sweats that last more than three weeks - Weight loss of more than 10% Silar adenopathy that is noticeable or chronic; symptoms that last longer than two months
• Prolonged chemotherapy is always recommended for individuals with disseminated illness. • During chemotherapy, pulmonary resection can be used to treat severe hemoptysis or cavities that burst or expand. In order to empty empyemas, seal persistent bronchopleural fistulas, or enlarge lungs that are constrained by lingering illness, surgery may also be necessary. • The preferred medications for treating meningeal illness are fluconazole and itraconazole. • The fact that azole therapy is well tolerated, does not have the toxic effects of amphotericin B, and does not require administration into the cerebrospinal fluid may represent significant advantages in patients with an otherwise fatal illness, even if C. immitis infection cannot be cured and lifelong suppression is necessary. Line Two Chemotherapy is nearly usually recommended once the illness has progressed outside of the lungs. Patients who do not respond to azole treatment are treated with amphotericin B.
PERMANENT CARE FOLLOW-UP ADVICE
• Residual sequelae, many of which have minimal long-term effects, are caused by 5–10% of infections. • The serologic response to C. immitis is typically at least qualitatively intact in those who are more susceptible to infection. The doctor should be aware of the probability of this diagnosis if the patient has a history of travel or residency in endemic areas. A postponed diagnosis can be avoided with routine serologic testing. • Ninety percent of meningitis patients die within a year if treatment is not received, thus early detection is crucial. • Some individuals develop chronic lung disease as a result of their acute pneumonia, which never goes away. This group is disproportionately overrepresented among individuals with diabetes and those with weakened immune systems.
COMPLICATIONS
• Immunocompromised people are more susceptible to the disease, especially if they have extrapulmonary coccidioidal disease. The first year following an organ transplant is the time when patients are most vulnerable to infection. • Meningitis may manifest clinically practically simultaneously with the initial infection and typically develops 6 months after it. Typically, there are no symptoms of meningeal irritation that are typical with bacterial meningitis. The headache is the most typical symptom. There may be focal neurologic problems, fever, weakness, disorientation, sluggishness, seizures, aberrant behavior, stiff neck, diplopia, ataxia, and vomiting.
- Published on
Infectious Disease – Chancroid
CHANCROID
ESSENTIALS DESCRIPTION
A sexually transmitted disease called chancroid first appears as sensitive genital lesions and thereafter as genital ulcers. Usually, a collection of excavated papules or pustules with a diameter of 2–20 mm and edges that are undermined, ragged, or uneven make up the original lesion.
The study of epidemiology
The prevalence
Chancroid typically happens in outbreaks in the United States. In 2009, the CDC received reports of 28 cases. The illness could go undiagnosed.
The frequency
Common throughout Asia, Latin America, and Africa
• Lower socioeconomic groups in the US
RISK ELEMENTS
• Having sex with several partners.
• Intercourse with a partner who has a Haemophilus ducreyi infection.
• Having sex with people in nations where chancroid is common.
• Patients with chancroid have a higher risk of HIV infection and transmission during sexual activity.
GENERAL PREVENTION: Steer clear of having intercourse with someone who has chancroid, genital lesions, or ulcers.
• Adhere to safe sexual behavior.
Etiology of H. ducreyi, a tiny, picky gram-negative rod that is frequently linked to
About 10% of those with chancroid that was contracted in the United States also have either herpes simplex virus (HSV) or Treponema pallidum.
History of Diagnosis
Time frame for incubation: 1–14 days
MEDICAL EXAMINATION
• Sensitive papules that, within a day or two, deteriorate, ulcerate, and turn pustular.
• Multiple lesions may combine to create a big ulcer that is more than 2 cm in diameter.
Around 40% of individuals have tender inguinal nodes, or "buboes."
• Occasionally, inguinal lymph nodes spontaneously burst and suppurate.
• Suppurative inguinal lymphadenopathy in conjunction with a severe genital ulcer.
Diagnostic Examination and Interpretation Laboratory
• Epidemiologic factors are used to make the first diagnosis.
those features of the lesions. Laboratory testing is crucial because a history and physical examination by themselves frequently result in a mistake.
• Special culture medium that are not generally accessible on the commercial market are necessary for the isolation of H. ducreyi in order to establish a conclusive diagnosis.
• H. ducreyi culture (80% sensitivity).
The 95% sensitivity of PCR (1). not authorized by the FDA. Not feasible for the majority of clinics.
• A dark-field examination, immunofluorescence test, or serologic test conducted more than seven days following the beginning of ulcers revealed no signs of syphilis.
• There is no clinical manifestation, HSV culture, or antigen test evidence of genital herpes. · At the time of diagnosis, get tested for HIV.
Diagnostic Techniques and Other
• Using a sterile gauze pad, gently rub the area to encourage seeping but avoid severe bleeding.
• To promote lesion exudate, squeeze the lesion between your gloved thumb and forefinger.
• When using exudate for direct immunofluorescence and dark-field studies, apply it directly onto a microscope slide.
Pathological Results
• The epidermis's superficial purulent exudate.
• HIV-infected individuals typically exhibit lower neutrophil infiltration; perivascular and interstitial mononuclear cells infiltrate in the dermis.
Acute HIV infection, genital herpes, syphilis, lymphogranuloma venereum, granuloma inguinale or donovanosis, mycobacteria, fungi, parasites, venereal warts, scabies, molluscum contagiosum, foliculitis, and plague are examples of differentiable diseases.
Erythema, dermatitis herpetiformis, trauma, cancer, and Behcet's syndrome are examples of noninfectious entities.
MEDICATION FOR TREATMENT
First Phrase
• One dose of 1 g of azithromycin p.o. (2)
• One dosage of 250 mg i.m. ceftriaxone (3)
Line Two
• 500 mg of ciprofloxacin b.i.d. for three days.
• 500 mg p.o. q.i.d. for seven days of erythromycin base (some specialists prefer this regimen for treating HIV-infected patients).
• There have been reports of many isolates with intermediate resistance to erythromycin or ciprofloxacin worldwide.
Considerations for Pregnancy
Pregnant and nursing women should not use ciprofloxacin. Chancroid has no negative impact on the outcome of pregnancy.
have been documented.
ADDITIONAL MEDICATION
Overall Actions
Within ten days of the patient's symptoms starting, assess and treat partners who have engaged in sexual activity with the patient. Utilize the same medications and dosages as before.
Other Treatments
For buboes, either incision and drainage or needle aspiration through nearby unbroken skin may be necessary. Because there is less need for repeat drainage, the latter might be selected.
Continuing Care Follow-Up Suggestions
· Check for evidence of ulcer improvement three to seven days after starting medication.
• The size of the ulcer determines how long it takes to heal completely; large ulcers may take longer than two weeks.
Uncircumcised males with ulcers under the foreskin heal more slowly, and those with fluctuant lymphadenopathy recover more slowly. • A failure to improve could indicate:
Diagnoses that are not correct; co-infection with another STD (such syphilis); and reinfection
Patients with HIV are more likely to have treatment failure.
Antimicrobial resistance and poor patient adherence to therapy
• If the first test results for HIV and syphilis were negative, patients should get retested for these conditions three months after being diagnosed with chancroid.
Education of Patients
Inform people about safe sexual behavior.
DIFFICULTIES
• Patients with chancroid have an increased risk of HIV infection and transmission during sexual activity; secondary ulcers or draining fistulas at the site of rupture of fluctuant lymphadenopathy.
CHANCROID
ESSENTIALS DESCRIPTION
A sexually transmitted disease called chancroid first appears as sensitive genital lesions and thereafter as genital ulcers. Usually, a collection of excavated papules or pustules with a diameter of 2–20 mm and edges that are undermined, ragged, or uneven make up the original lesion.
The study of epidemiology
The prevalence
Chancroid typically happens in outbreaks in the United States. In 2009, the CDC received reports of 28 cases. The illness could go undiagnosed.
The frequency
Common throughout Asia, Latin America, and Africa
• Lower socioeconomic groups in the US
RISK ELEMENTS
• Having sex with several partners.
• Intercourse with a partner who has a Haemophilus ducreyi infection.
• Having sex with people in nations where chancroid is common.
• Patients with chancroid have a higher risk of HIV infection and transmission during sexual activity.
GENERAL PREVENTION: Steer clear of having intercourse with someone who has chancroid, genital lesions, or ulcers.
• Adhere to safe sexual behavior.
Etiology of H. ducreyi, a tiny, picky gram-negative rod that is frequently linked to
About 10% of those with chancroid that was contracted in the United States also have either herpes simplex virus (HSV) or Treponema pallidum.
History of Diagnosis
Time frame for incubation: 1–14 days
MEDICAL EXAMINATION
• Sensitive papules that, within a day or two, deteriorate, ulcerate, and turn pustular.
• Multiple lesions may combine to create a big ulcer that is more than 2 cm in diameter.
Around 40% of individuals have tender inguinal nodes, or "buboes."
• Occasionally, inguinal lymph nodes spontaneously burst and suppurate.
• Suppurative inguinal lymphadenopathy in conjunction with a severe genital ulcer.
Diagnostic Examination and Interpretation Laboratory
• Epidemiologic factors are used to make the first diagnosis.
those features of the lesions. Laboratory testing is crucial because a history and physical examination by themselves frequently result in a mistake.
• Special culture medium that are not generally accessible on the commercial market are necessary for the isolation of H. ducreyi in order to establish a conclusive diagnosis.
• H. ducreyi culture (80% sensitivity).
The 95% sensitivity of PCR (1). not authorized by the FDA. Not feasible for the majority of clinics.
• A dark-field examination, immunofluorescence test, or serologic test conducted more than seven days following the beginning of ulcers revealed no signs of syphilis.
• There is no clinical manifestation, HSV culture, or antigen test evidence of genital herpes. · At the time of diagnosis, get tested for HIV.
Diagnostic Techniques and Other
• Using a sterile gauze pad, gently rub the area to encourage seeping but avoid severe bleeding.
• To promote lesion exudate, squeeze the lesion between your gloved thumb and forefinger.
• When using exudate for direct immunofluorescence and dark-field studies, apply it directly onto a microscope slide.
Pathological Results
• The epidermis's superficial purulent exudate.
• HIV-infected individuals typically exhibit lower neutrophil infiltration; perivascular and interstitial mononuclear cells infiltrate in the dermis.
Acute HIV infection, genital herpes, syphilis, lymphogranuloma venereum, granuloma inguinale or donovanosis, mycobacteria, fungi, parasites, venereal warts, scabies, molluscum contagiosum, foliculitis, and plague are examples of differentiable diseases.
Erythema, dermatitis herpetiformis, trauma, cancer, and Behcet's syndrome are examples of noninfectious entities.
MEDICATION FOR TREATMENT
First Phrase
• One dose of 1 g of azithromycin p.o. (2)
• One dosage of 250 mg i.m. ceftriaxone (3)
Line Two
• 500 mg of ciprofloxacin b.i.d. for three days.
• 500 mg p.o. q.i.d. for seven days of erythromycin base (some specialists prefer this regimen for treating HIV-infected patients).
• There have been reports of many isolates with intermediate resistance to erythromycin or ciprofloxacin worldwide.
Considerations for Pregnancy
Pregnant and nursing women should not use ciprofloxacin. Chancroid has no negative impact on the outcome of pregnancy.
have been documented.
ADDITIONAL MEDICATION
Overall Actions
Within ten days of the patient's symptoms starting, assess and treat partners who have engaged in sexual activity with the patient. Utilize the same medications and dosages as before.
Other Treatments
For buboes, either incision and drainage or needle aspiration through nearby unbroken skin may be necessary. Because there is less need for repeat drainage, the latter might be selected.
Continuing Care Follow-Up Suggestions
· Check for evidence of ulcer improvement three to seven days after starting medication.
• The size of the ulcer determines how long it takes to heal completely; large ulcers may take longer than two weeks.
Uncircumcised males with ulcers under the foreskin heal more slowly, and those with fluctuant lymphadenopathy recover more slowly. • A failure to improve could indicate:
Diagnoses that are not correct; co-infection with another STD (such syphilis); and reinfection
Patients with HIV are more likely to have treatment failure.
Antimicrobial resistance and poor patient adherence to therapy
• If the first test results for HIV and syphilis were negative, patients should get retested for these conditions three months after being diagnosed with chancroid.
Education of Patients
Inform people about safe sexual behavior.
DIFFICULTIES
• Patients with chancroid have an increased risk of HIV infection and transmission during sexual activity; secondary ulcers or draining fistulas at the site of rupture of fluctuant lymphadenopathy.
- Published on
Infectious Disease - Cholangitis/Cholecystitis
DESCRIPTION: Cholangitis is a clinical diagnosis based on symptoms and indicators of systemic sepsis that originate in the biliary tract, while cholecystitis is an acute or chronic inflammation of the gallbladder.
• Gallbladder inflammation, also known as gaseous cholecystitis, is typified by gas in the gallbladder lumen that may penetrate the gallbladder wall and/or surrounding tissues.
EPIDEMIOLOGY • Three to ten percent of patients with stomach pain have acute cholecystitis. In patients older than 50, the frequency rises to 20%.
• Biliary colic affects 1–4% of cholelithiasis patients each year. Twenty percent of people with symptoms go on to develop acute cholecystitis if they are not treated.
RISK ELEMENTS
• Cholelithiasis is the cause of 90–95% of acute cholecystitis cases.
• The risk of cholelithiasis and cholecystitis is elevated by both obesity and severe dieting.
• Hemolytic disorders, such as sickle cell disease and G6PD deficiency, raise the incidence of pigment stones and the biliary blockage that follows.
• Some ethnic groups, like Pima Indians, are more likely to experience stone formation.
Diabetes mellitus, ischemia, sepsis, and other low-flow states; motility disorders; severe burns or trauma; direct chemical injury; allergic reactions; prolonged use of total parenteral nutrition; vasculitis; collagen disease; sarcoidosis; infections (such as TB, actinomycosis, ascariasis, and HIV/AIDS); and gallbladder torsion are all linked to acalculous cholecystitis.
– In AIDS patients, acalculous cholecystitis usually develops earlier in life and is linked to infections with the cytomegalovirus (CMV) and cryptosporidium.
• Patients with diabetes mellitus and the elderly are more likely to develop emphysematous cholecystitis.
• An infectious consequence of retrograde endoscopic cholangiopancreatography (ERCP).
Considerations for Pregnancy
Although cholelithiasis is common during pregnancy, it is unknown if cholecystitis is also more common during this time.
Genetics • Although cholecystitis tends to be more severe in men, gallstones are more than twice as common in women than in men.
The incidence of acalculous cholecystitis is somewhat higher in men.
OVERALL PREVENTION
Gallstone development can be avoided with a low-fat diet. Acute cholecystitis has also become less common when biliary colic is treated with stone removal or cholecystectomy.
PATHOPHYSIOLOGY Gallstone blockage is the cause of acute calculous cholecystitis.
Gallbladder stasis and stagnated bile cause acalculous cholecystitis.
• Common bile duct blockage causes acute cholangitis, which is accompanied by elevated biliary
pressures. Cholangitis symptoms may arise from the movement of bacteria or endotoxins from the bile ducts into the circulation and lymphatic systems due to obstruction.
ETIOLOGY • Progesterone, fibrate, estrogen, ceftriaxone, and octreotide are among the drugs that have been linked to the development of cholestasis or gallstone formation that results in acute cholecystitis. Additional medications linked to cholecystitis include dapsone, which promotes hemolysis, erythromycin and ampicillin hypersensitivity, and opioids and anticholinergic drugs, which impair gallbladder motility.
• Polymicrobial illnesses predominate. Escherichia coli, Klebsiella species, Enterococcus species, Enterobacter species, and Pseudomonas species are the most frequently cultured organisms. Following surgery or an interventional endoscopy, Staphylococcus and Pseudomonas may be discovered. Patients with diabetes, the elderly, and those recovering from biliary system surgeries are more likely to have anaerobes.
• Choledocholithiasis, malignant biliary strictures, iatrogenic bile duct damage, and stricture of the bile duct are obstructive lesions that increase the risk of pyogenic bacterial cholangitis.
primary sclerosing cholangitis, congenital intrahepatic biliary dilatation (Caroli's disease), biliary anastomosis, and parasite entrance into the bile duct. The trematodes Clonorchis and Opisthorchis, the nematodes Ascaris and, infrequently, Strongyloides, and the cestodes Echinococcus granulosus and Echinococcus multilocularis are among the parasites linked to cholangitis.
History of Diagnosis
• Abdominal pain in the right upper quadrant that may radiate to the infrascapular region is a common symptom of biliary tract disease.
• Acute cholecystitis frequently starts with a fever and biliary colic attack that gets worse over time.
– A history of previous assaults that ended on their own is reported by 60–70% of patients.
– Cholecystitis (and cholangitis) causes constant pain, in contrast to biliary colic.
• Undefined stomach pain or an inexplicable fever are two symptoms of acalculous cholecystitis. Particularly in critically ill patients who are not responding, a high index of suspicion is necessary.
• The symptoms of acute cholangitis frequently include fever and chills, jaundice, and discomfort in the right upper quadrant (Charcot's triad).
– Charcot's triad is only present in 50–70% of patients. Lethargy, mental disorientation, and shock (Reynolds' pentad) are further presenting symptoms.
– Disseminated intravascular coagulation and renal failure are other indicators of organ failure.
Physical examination: Tenderness in the right upper quadrant of the abdomen is 98% sensitive to biliary tract illness. The palpation of a mass in the right upper quadrant is one of the other less sensitive findings. Abdominal discomfort in the right upper quadrant is one of the findings that point to biliary tract disease.
• Acute cholecystitis can be detected by the presence of a Murphy's sign, which is pain felt when the right subcostal region is palpated during inspiration.
Tests for Diagnosis and Interpretation Lab
• Fever and leukocytosis are common symptoms in patients with acute cholecystitis.
WBC count >12,500 cells/mm3 or temperature >38.5°C indicate the presence of infection.
The severity of the condition is indicated by anomalies in the BUN, Cr, platelet count, and prothrombin time.
• Half of patients had slightly raised serum bilirubin, and 25% have slightly elevated serum aminotransferases.
• There is frequently an increase in C-reactive protein.
• Concomitant gallstone pancreatitis or gangrenous cholecystitis may be indicated by elevated amylase values.
• 90% of patients with choledocholithiasis and jaundice have positive biliary cultures, while 50% of patients with biliary blockage do. Incomplete bile duct obstruction is more likely to result in positive cultures than full obstruction. Although bacterial colonization is typically linked to advanced age (>70 years), prior biliary system operations, and common duct stones, bile in healthy persons is typically sterile.
Imagining
• The diagnosis of cholecystitis is often established by ultrasound.
– Gallbladder wall thickening greater than 2 mm, pericholecystic fluid, intramural gas, ductal dilatation, or direct discomfort when the probe is put over the gallbladder (sonographic Murphy's sign) are all signs of acute cholecystitis.
– A sonographic Murphy's sign and the presence of stones have a 92% positive predictive value (PPV).
– The gallbladder wall thickening and stone presence had a 95% PPV.
– When there are no stones and a normal gallbladder wall or Murphy's sign is missing, the negative predictive value is 95%.
Diagnostic Techniques and Other
• Hepatobiliary scintigraphy uses an intravenous injection of technetium-labeled iminodiacetic acid analogs to monitor the flow of bile. It is 80–90% sensitive for acute cholecystitis and shows occlusion of the cystic duct if there is no gallbladder filling 60 minutes after treatment. Usually utilized when ultrasonography is not diagnostic, the false positive rate ranges from 10% to 20%.
• When used in conjunction with US to diagnose cholangitis, CT with intravenous contrast may show pneumobilia and bile duct dilatation.
TREATMENT MEDICATION
Patients with acute cholecystitis or cholangitis should receive antibiotics that target Enterobacteriaceae.
For mild-to-moderate instances of community-acquired acute cholecystitis, the Infectious Diseases Society of America advises using cefazolin, cefuroxime, or ceftriaxone.
• Vancomycin should be added to healthcare-associated biliary infections of any severity. • Broad-spectrum antibiotic therapy, such as imipenem-cilastatin, meropenem, piperacillin-tazobactam, ciprofloxacin, levofloxacin, or cefepime, is advised for acute cholangitis or acute cholecystitis in the presence of advanced age, immunocompromised patients, or severe physiologic disturbance.
Give antibiotics as a preventative measure for cholecystectomy or to patients who have diabetes, immunodeficiency, or advanced age.
• Start taking antibiotics an hour before and stop taking them
• antibiotics for acute cholecystitis without signs of infection outside the gallbladder within 24 hours of cholecystectomy.
Since the pathogenicity of enterococci in immunocompetent hosts has not been established, anti-enterococcal medication is not necessary for community-acquired biliary infections in these individuals.
• In the event that post-operative difficulties develop, intra-operative gallbladder bile cultures may be utilized to inform antibiotic selection.
• Systemic antibiotics and, in cases of more severe illness, biliary drainage are used to treat acute cholangitis.
ADDITIONAL MEDICATION
Overall Actions
• Correct fluid status and electrolyte imbalances with intravenous fluids; • Stop oral intake and start nasogastric suction.
• The most common analgesics are meperidine or pentazocine.
OTHER PROCEDURES AND SURGERY
• Because to the lower rate of complications, fewer expenses, and shorter recovery times, early cholecystectomy is preferable over delayed (post-"cooling off") cholecystectomy.
• Biliary decompression can be achieved via endoscopic gallbladder draining and stenting or percutaneous transhepatic gallbladder aspiration, in addition to open or laparoscopic cholecystectomy.
• When a gallbladder perforation or emphysematous cholecystitis, two complications of acute cholecystitis, are suspected or confirmed, an urgent cholecystectomy is necessary.
• In cases of acute cholangitis, biliary drainage can be carried out percutaneously or via endoscopy (ERCP). It might be necessary to use emergency surgical drainage.
PROGNOSIS FOR ONGOING CARE • Of the 75% of patients with acute cholecystitis whose symptoms resolve, around a quarter will relapse within a year, and 60% will have at least one recurrent episode within six years.
• Acute cholangitis has a mortality rate of 10–30%.
DIFFICULTIES
• Chronic cholecystitis can be brought on by recurrent episodes of mild acute cholecystitis or by long-term irritation from big gallstones.
• Acalculous cholecystitis has a higher rate of complications than calculous cholecystitis.
• Gallbladder empyema carries a substantial risk of perforation and/or Gram-negative sepsis.
• Inflammation and adhesion development may cause fistulization into a nearby organ that is adherent to the gallbladder wall.
• Elderly people are far more likely than younger patients to experience severe acute cholangitis (along by shock or mental impairment).
• Sepsis and hepatic abscess are possible outcomes of acute cholangitis.
• Cholangitis may be obscured by an enlarged and painful liver caused by the abscess.
DESCRIPTION: Cholangitis is a clinical diagnosis based on symptoms and indicators of systemic sepsis that originate in the biliary tract, while cholecystitis is an acute or chronic inflammation of the gallbladder.
• Gallbladder inflammation, also known as gaseous cholecystitis, is typified by gas in the gallbladder lumen that may penetrate the gallbladder wall and/or surrounding tissues.
EPIDEMIOLOGY • Three to ten percent of patients with stomach pain have acute cholecystitis. In patients older than 50, the frequency rises to 20%.
• Biliary colic affects 1–4% of cholelithiasis patients each year. Twenty percent of people with symptoms go on to develop acute cholecystitis if they are not treated.
RISK ELEMENTS
• Cholelithiasis is the cause of 90–95% of acute cholecystitis cases.
• The risk of cholelithiasis and cholecystitis is elevated by both obesity and severe dieting.
• Hemolytic disorders, such as sickle cell disease and G6PD deficiency, raise the incidence of pigment stones and the biliary blockage that follows.
• Some ethnic groups, like Pima Indians, are more likely to experience stone formation.
Diabetes mellitus, ischemia, sepsis, and other low-flow states; motility disorders; severe burns or trauma; direct chemical injury; allergic reactions; prolonged use of total parenteral nutrition; vasculitis; collagen disease; sarcoidosis; infections (such as TB, actinomycosis, ascariasis, and HIV/AIDS); and gallbladder torsion are all linked to acalculous cholecystitis.
– In AIDS patients, acalculous cholecystitis usually develops earlier in life and is linked to infections with the cytomegalovirus (CMV) and cryptosporidium.
• Patients with diabetes mellitus and the elderly are more likely to develop emphysematous cholecystitis.
• An infectious consequence of retrograde endoscopic cholangiopancreatography (ERCP).
Considerations for Pregnancy
Although cholelithiasis is common during pregnancy, it is unknown if cholecystitis is also more common during this time.
Genetics • Although cholecystitis tends to be more severe in men, gallstones are more than twice as common in women than in men.
The incidence of acalculous cholecystitis is somewhat higher in men.
OVERALL PREVENTION
Gallstone development can be avoided with a low-fat diet. Acute cholecystitis has also become less common when biliary colic is treated with stone removal or cholecystectomy.
PATHOPHYSIOLOGY Gallstone blockage is the cause of acute calculous cholecystitis.
Gallbladder stasis and stagnated bile cause acalculous cholecystitis.
• Common bile duct blockage causes acute cholangitis, which is accompanied by elevated biliary
pressures. Cholangitis symptoms may arise from the movement of bacteria or endotoxins from the bile ducts into the circulation and lymphatic systems due to obstruction.
ETIOLOGY • Progesterone, fibrate, estrogen, ceftriaxone, and octreotide are among the drugs that have been linked to the development of cholestasis or gallstone formation that results in acute cholecystitis. Additional medications linked to cholecystitis include dapsone, which promotes hemolysis, erythromycin and ampicillin hypersensitivity, and opioids and anticholinergic drugs, which impair gallbladder motility.
• Polymicrobial illnesses predominate. Escherichia coli, Klebsiella species, Enterococcus species, Enterobacter species, and Pseudomonas species are the most frequently cultured organisms. Following surgery or an interventional endoscopy, Staphylococcus and Pseudomonas may be discovered. Patients with diabetes, the elderly, and those recovering from biliary system surgeries are more likely to have anaerobes.
• Choledocholithiasis, malignant biliary strictures, iatrogenic bile duct damage, and stricture of the bile duct are obstructive lesions that increase the risk of pyogenic bacterial cholangitis.
primary sclerosing cholangitis, congenital intrahepatic biliary dilatation (Caroli's disease), biliary anastomosis, and parasite entrance into the bile duct. The trematodes Clonorchis and Opisthorchis, the nematodes Ascaris and, infrequently, Strongyloides, and the cestodes Echinococcus granulosus and Echinococcus multilocularis are among the parasites linked to cholangitis.
History of Diagnosis
• Abdominal pain in the right upper quadrant that may radiate to the infrascapular region is a common symptom of biliary tract disease.
• Acute cholecystitis frequently starts with a fever and biliary colic attack that gets worse over time.
– A history of previous assaults that ended on their own is reported by 60–70% of patients.
– Cholecystitis (and cholangitis) causes constant pain, in contrast to biliary colic.
• Undefined stomach pain or an inexplicable fever are two symptoms of acalculous cholecystitis. Particularly in critically ill patients who are not responding, a high index of suspicion is necessary.
• The symptoms of acute cholangitis frequently include fever and chills, jaundice, and discomfort in the right upper quadrant (Charcot's triad).
– Charcot's triad is only present in 50–70% of patients. Lethargy, mental disorientation, and shock (Reynolds' pentad) are further presenting symptoms.
– Disseminated intravascular coagulation and renal failure are other indicators of organ failure.
Physical examination: Tenderness in the right upper quadrant of the abdomen is 98% sensitive to biliary tract illness. The palpation of a mass in the right upper quadrant is one of the other less sensitive findings. Abdominal discomfort in the right upper quadrant is one of the findings that point to biliary tract disease.
• Acute cholecystitis can be detected by the presence of a Murphy's sign, which is pain felt when the right subcostal region is palpated during inspiration.
Tests for Diagnosis and Interpretation Lab
• Fever and leukocytosis are common symptoms in patients with acute cholecystitis.
WBC count >12,500 cells/mm3 or temperature >38.5°C indicate the presence of infection.
The severity of the condition is indicated by anomalies in the BUN, Cr, platelet count, and prothrombin time.
• Half of patients had slightly raised serum bilirubin, and 25% have slightly elevated serum aminotransferases.
• There is frequently an increase in C-reactive protein.
• Concomitant gallstone pancreatitis or gangrenous cholecystitis may be indicated by elevated amylase values.
• 90% of patients with choledocholithiasis and jaundice have positive biliary cultures, while 50% of patients with biliary blockage do. Incomplete bile duct obstruction is more likely to result in positive cultures than full obstruction. Although bacterial colonization is typically linked to advanced age (>70 years), prior biliary system operations, and common duct stones, bile in healthy persons is typically sterile.
Imagining
• The diagnosis of cholecystitis is often established by ultrasound.
– Gallbladder wall thickening greater than 2 mm, pericholecystic fluid, intramural gas, ductal dilatation, or direct discomfort when the probe is put over the gallbladder (sonographic Murphy's sign) are all signs of acute cholecystitis.
– A sonographic Murphy's sign and the presence of stones have a 92% positive predictive value (PPV).
– The gallbladder wall thickening and stone presence had a 95% PPV.
– When there are no stones and a normal gallbladder wall or Murphy's sign is missing, the negative predictive value is 95%.
Diagnostic Techniques and Other
• Hepatobiliary scintigraphy uses an intravenous injection of technetium-labeled iminodiacetic acid analogs to monitor the flow of bile. It is 80–90% sensitive for acute cholecystitis and shows occlusion of the cystic duct if there is no gallbladder filling 60 minutes after treatment. Usually utilized when ultrasonography is not diagnostic, the false positive rate ranges from 10% to 20%.
• When used in conjunction with US to diagnose cholangitis, CT with intravenous contrast may show pneumobilia and bile duct dilatation.
TREATMENT MEDICATION
Patients with acute cholecystitis or cholangitis should receive antibiotics that target Enterobacteriaceae.
For mild-to-moderate instances of community-acquired acute cholecystitis, the Infectious Diseases Society of America advises using cefazolin, cefuroxime, or ceftriaxone.
• Vancomycin should be added to healthcare-associated biliary infections of any severity. • Broad-spectrum antibiotic therapy, such as imipenem-cilastatin, meropenem, piperacillin-tazobactam, ciprofloxacin, levofloxacin, or cefepime, is advised for acute cholangitis or acute cholecystitis in the presence of advanced age, immunocompromised patients, or severe physiologic disturbance.
Give antibiotics as a preventative measure for cholecystectomy or to patients who have diabetes, immunodeficiency, or advanced age.
• Start taking antibiotics an hour before and stop taking them
• antibiotics for acute cholecystitis without signs of infection outside the gallbladder within 24 hours of cholecystectomy.
Since the pathogenicity of enterococci in immunocompetent hosts has not been established, anti-enterococcal medication is not necessary for community-acquired biliary infections in these individuals.
• In the event that post-operative difficulties develop, intra-operative gallbladder bile cultures may be utilized to inform antibiotic selection.
• Systemic antibiotics and, in cases of more severe illness, biliary drainage are used to treat acute cholangitis.
ADDITIONAL MEDICATION
Overall Actions
• Correct fluid status and electrolyte imbalances with intravenous fluids; • Stop oral intake and start nasogastric suction.
• The most common analgesics are meperidine or pentazocine.
OTHER PROCEDURES AND SURGERY
• Because to the lower rate of complications, fewer expenses, and shorter recovery times, early cholecystectomy is preferable over delayed (post-"cooling off") cholecystectomy.
• Biliary decompression can be achieved via endoscopic gallbladder draining and stenting or percutaneous transhepatic gallbladder aspiration, in addition to open or laparoscopic cholecystectomy.
• When a gallbladder perforation or emphysematous cholecystitis, two complications of acute cholecystitis, are suspected or confirmed, an urgent cholecystectomy is necessary.
• In cases of acute cholangitis, biliary drainage can be carried out percutaneously or via endoscopy (ERCP). It might be necessary to use emergency surgical drainage.
PROGNOSIS FOR ONGOING CARE • Of the 75% of patients with acute cholecystitis whose symptoms resolve, around a quarter will relapse within a year, and 60% will have at least one recurrent episode within six years.
• Acute cholangitis has a mortality rate of 10–30%.
DIFFICULTIES
• Chronic cholecystitis can be brought on by recurrent episodes of mild acute cholecystitis or by long-term irritation from big gallstones.
• Acalculous cholecystitis has a higher rate of complications than calculous cholecystitis.
• Gallbladder empyema carries a substantial risk of perforation and/or Gram-negative sepsis.
• Inflammation and adhesion development may cause fistulization into a nearby organ that is adherent to the gallbladder wall.
• Elderly people are far more likely than younger patients to experience severe acute cholangitis (along by shock or mental impairment).
• Sepsis and hepatic abscess are possible outcomes of acute cholangitis.
• Cholangitis may be obscured by an enlarged and painful liver caused by the abscess.
- Published on
CHRONIC FATIGUE SYNDROME
BASICS DESCRIPTION: Chronic fatigue syndrome (CFS) is a diverse condition that causes extreme, incapacitating fatigue that lasts for at least six months.
Considerations for Children
• Seldom seen in kids.
• As the counterpart of an adult handicap, absenteeism from activities or school should be tracked.
The study of epidemiology
In the US, the prevalence ranges from 4.0 to 8.7 per 100,000 (2). • Prevalence: 0.6–1% globally.
RISK ELEMENTS
Gender: women are 2-3 times more likely to have it. Genetics
ongoing investigation to see if any particular genes are connected to CFS.
Pathophysiology
Not sure.
ETIOLOGY: Unknown.
• There have been hypothesized but unsubstantiated correlations with EBV, CMV, HHV, HCV, Borrelia burgdorferi, and Brucella.
• Possible links to immunological or neuroendocrine conditions, including those involving the autonomic nervous system or the hypothalamic-pituitary-adrenal axis.
COMMON CONNECTED CIRCUMSTANCES
Depressive symptoms and fibromyalgia
History of Diagnosis
• Severe exhaustion that has persisted for over six months and has not gone away with rest.
• Four of the symptoms listed below:
Post-exercise malaise: Sleep that doesn't alleviate weariness
A diminished capacity for memory or focus
Muscle pain; joint pain in several places without heat or swelling; cervical or axillary lymph node pain; sore throat; headache
PHYSICAL EXAMINATION: Although it is possible, painful lymphadenopathy is not necessary for diagnosis.
• Minimal outward signs.
TESTS FOR DIAGNOSIS AND INTERPRETATION
Lab
as required to take into account additional causes of weariness.
Imagining
Not advised.
Diagnostic Techniques and Other
clinical history-based diagnosis of exclusion, in accordance with the 1994 CDC criteria.
There are no pathological findings.
DIFFERENTIAL DIAGNOSIS: Lyme disease, depression, epilepsy, brucellosis, CMV, Epstein-Barr virus, and HIV infection
Brain tumors, tumors with paraneoplastic syndrome, and collagen-vascular diseases
MEDICAL CARE
supportive actions listed below.
MEDICATION Antidepressants along with other forms of treatment.
ADDITIONAL MEDICATION
Overall Actions
a focus on several treatment approaches with the aim of gradual progress over time.
Other Treatments
CBT, or cognitive behavioral treatment, is one (1) example.
A regimen called graded exercise treatment helps people with CFS avoid the "push-crash" cycle, which is characterized by overexertion followed by post-exertional malaise.
Throughout the day, schedule shorter bursts of moderate activity to lower the risk of "push-
crash" cycle. combines exercise and cognitive behavioral therapy. • Good sleep habits.
• Research on sleep.
ALTERNATIVE AND COMPLIMENTARY THERAPIES
• Deep breathing and other relaxing methods; • Massage Tai chi, yoga, and healing touch
Continuing Care Follow-Up Suggestions
It is advised to follow up with a multidisciplinary team of providers on a regular basis.
PROGNOSIS
• It takes a long time to get diagnosed (around five years on average). • Symptom improvement: 6–63%.
• Symptom resolution: 0–37%.
BASICS DESCRIPTION: Chronic fatigue syndrome (CFS) is a diverse condition that causes extreme, incapacitating fatigue that lasts for at least six months.
Considerations for Children
• Seldom seen in kids.
• As the counterpart of an adult handicap, absenteeism from activities or school should be tracked.
The study of epidemiology
In the US, the prevalence ranges from 4.0 to 8.7 per 100,000 (2). • Prevalence: 0.6–1% globally.
RISK ELEMENTS
Gender: women are 2-3 times more likely to have it. Genetics
ongoing investigation to see if any particular genes are connected to CFS.
Pathophysiology
Not sure.
ETIOLOGY: Unknown.
• There have been hypothesized but unsubstantiated correlations with EBV, CMV, HHV, HCV, Borrelia burgdorferi, and Brucella.
• Possible links to immunological or neuroendocrine conditions, including those involving the autonomic nervous system or the hypothalamic-pituitary-adrenal axis.
COMMON CONNECTED CIRCUMSTANCES
Depressive symptoms and fibromyalgia
History of Diagnosis
• Severe exhaustion that has persisted for over six months and has not gone away with rest.
• Four of the symptoms listed below:
Post-exercise malaise: Sleep that doesn't alleviate weariness
A diminished capacity for memory or focus
Muscle pain; joint pain in several places without heat or swelling; cervical or axillary lymph node pain; sore throat; headache
PHYSICAL EXAMINATION: Although it is possible, painful lymphadenopathy is not necessary for diagnosis.
• Minimal outward signs.
TESTS FOR DIAGNOSIS AND INTERPRETATION
Lab
as required to take into account additional causes of weariness.
Imagining
Not advised.
Diagnostic Techniques and Other
clinical history-based diagnosis of exclusion, in accordance with the 1994 CDC criteria.
There are no pathological findings.
DIFFERENTIAL DIAGNOSIS: Lyme disease, depression, epilepsy, brucellosis, CMV, Epstein-Barr virus, and HIV infection
Brain tumors, tumors with paraneoplastic syndrome, and collagen-vascular diseases
MEDICAL CARE
supportive actions listed below.
MEDICATION Antidepressants along with other forms of treatment.
ADDITIONAL MEDICATION
Overall Actions
a focus on several treatment approaches with the aim of gradual progress over time.
Other Treatments
CBT, or cognitive behavioral treatment, is one (1) example.
A regimen called graded exercise treatment helps people with CFS avoid the "push-crash" cycle, which is characterized by overexertion followed by post-exertional malaise.
Throughout the day, schedule shorter bursts of moderate activity to lower the risk of "push-
crash" cycle. combines exercise and cognitive behavioral therapy. • Good sleep habits.
• Research on sleep.
ALTERNATIVE AND COMPLIMENTARY THERAPIES
• Deep breathing and other relaxing methods; • Massage Tai chi, yoga, and healing touch
Continuing Care Follow-Up Suggestions
It is advised to follow up with a multidisciplinary team of providers on a regular basis.
PROGNOSIS
• It takes a long time to get diagnosed (around five years on average). • Symptom improvement: 6–63%.
• Symptom resolution: 0–37%.
- Published on
Infectious Disease - Varicella or chickenpox
ESSENTIALS DESCRIPTION
A rash with concurrently present various stages of evolution (containing combinations of macules, papules, vesicles, and pustules) is the hallmark of chickenpox, a feverish, highly contagious illness that typically affects young children and is caused by a primary infection with the varicella zoster virus (VZV).
The study of epidemiology
The prevalence
• It is found all throughout the world and manifests as outbreaks in the late winter and early spring.
• 90% of vulnerable subjects experience a primary attack, and 70–90% of the same family experiences a secondary attack.
• Because of the immunization campaign, the incidence is declining (1). The frequency
• In two US towns where varicella is recorded, the incidence decreased by 90% between 1995 and 2005 as a result of vaccination (2).
• Moreover, related deaths, complications, expenses, and hospitalizations have decreased (2).
Males and females are the dominant sexes.
• Close contact between a nonimmune individual and a patient who is spreading the virus (exposure to varicella or herpes zoster) is a risk factor.
About 90% of occurrences occur in youngsters under the age of three. • Of people aged ≥15, 90% are immune, whereas 10% are still vulnerable.
• The number of instances in adulthood is rising.
OVERALL PREVENTION
Until the patient is no longer contagious, they must be kept out of school: Until all of the vesicles have crusted, a patient is contagious 48 hours before the rash appears (at the conclusion of the incubation period).
Immunization via Passive
• Varicella zoster immunoglobulin ought to be administered subsequent to
exposure to cases of herpes zoster or chickenpox in the following groups: susceptible pregnant women; susceptible immunocompetent adults and adolescents; and susceptible immunocompromised youngsters
- newborns born to mothers who contract chickenpox five days prior to or two days following delivery - Premature newborns admitted to hospitals (birth weight <1000 g, regardless of maternal history, or ≥28 weeks gestation when mother has no history chickenpox)< />pan>
• It should be injected intramuscularly within 96 hours, ideally within 72 hours, of exposure. Newborns receive 125U, while everyone else receives 125U/10 kg body weight (up to 625U).
Vaccination: Since 1995, the US has licensed the live attenuated VZV vaccine (Varivax: 0.5 mL s.c.) (1). In the United States, children older than 12 months are typically advised to receive two doses of this vaccination (3).
• Attenuated virus vaccination at ages 4–6 years and 12–15 months. With a minimum of three months between doses, the second dose may be given prior to age four (3).
• Children between the ages of 12 months and 12 years must wait at least 3 months between doses; however, if the gap is at least 28 days, the second dose may be accepted. For kids who are at least 13 years old, the minimum
There is a 28-day gap between dosages (3).
• It is recommended that adults without a history of chickenpox who have not received the vaccination receive it. Give two doses separated by at least 28 days if you have never been vaccinated, or the second dose if you have received just one dose (3).
• The VZV vaccine can also be given in combination with the measles, mumps, rubella, and varicella vaccines.
Pathophysiology
The respiratory mucous membranes allow the virus to enter the body, where it multiplies in local lymph nodes. Primary cell associated viremia is the means by which peripheral blood mononuclear cells become infected. The virus spreads to cutaneous epithelial cells by a secondary viremia. In ganglia, it stays dormant for life (4).
ETIOLOGY • Varicella zoster virus (HHV-3, DNA virus, genus: Varicellovirus, family: Herpesviridae).
• VZV does not have a recognized animal reservoir. The only reservoir is humans.
• Person-to-person contact is the means of transmission; the virus replicates in the nasopharynx or upper respiratory tract and is transmitted through the respiratory system and vesicle fluid.
respiratory system.
History of Diagnosis
• The duration of incubation is 10–14 days, with a range of 10–21 days.
• Affected systems include the skin, respiratory, central nervous system, disseminated/viremia, and other viscera.
Children who are immunocompetent may experience prodromal symptoms 1-2 days before the rash appears. low-grade fever and malaise.
• Constitutional symptoms include anorexia, pruritus, malaise, low-grade fever, and listlessness.
Rash.
Patients with weakened immune systems
• A greater number of hemorrhagic-based lesions.
• Three times longer healing time.
• More likely to experience visceral problems (30–50% of instances; 15% of those are deadly).
Adults
• A more serious condition. • A higher chance of visceral problems.
Women Who Are Expectant
more susceptible to congenital transmission to the fetus and maternal pneumonia (4).
Varicella in perinatal
• High mortality rate (30%) • Progressive disease involving viscera, especially the lung, and death in the infant may result from the mother contracting chickenpox 5 days prior to delivery and 48 hours following.
Varicella congenital
Severe deformities (skin scarring, hypoplastic extremities, anomalies of the eyes, and CNS dysfunction) can result from a teratogenic virus infection of the fetus during the first two trimesters of pregnancy.
MEDICAL EXAMINATION
• Rash: Spreads centripetally from the face and trunk. Mucous membranes may be affected, and
the vagina. Maculopapular at first, it transforms into vesicles that contain transparent fluid. After a few hours, the fluid becomes purulent. Lesions range in size from 5 to 13 mm in diameter, round or oval, and have an erythematous base. As the healing process advances, central umbilication emerges. The development of new lesions is followed and coexisted with by crust formation. Every type of lesion is simultaneously present at different phases of development. Lesions typically develop in subsequent crops over a period of two to four days.
• Within a week or two of commencement, the crusts break off, leaving a slightly depressed patch of skin that is scar-free unless it is superinfected.
Diagnostic Examinations and Interpretation Laboratory
Although the diagnosis is primarily clinical, it should be remembered that novice doctors have little knowledge of chickenpox (1).
PCR analysis of a clinical samples to detect VZV DNA (1, 5). The most dependable technique is PCR.
It takes roughly three days to isolate VZV from material extracted from the bottom of the lesions (viral culture).
Multinucleated giant cells are visible in a Tzanck smear taken from the bottom of a vesicle.
VZV detection in smears using direct
tests such as immunofluorescence staining (DFA).
• Serology: Convalescent serum samples with a fourfold or higher rise in IgG antibody (ELISA test) or seroconversion (positive IgM antibody). There may not be a fourfold rise in vaccinated subjects (5). Imagining
• Only 10% of individuals with positive chest x-rays experience clinical respiratory symptoms; 16% of chickenpox patients have abnormalities in their chest x-rays.
• Increased reticular shadowing or a nodular pattern are signs of pneumonitis.
DISTINCTIVE DIAGNOSIS
• Infection with the herpes simplex virus that spreads among atopic dermatitis patients.
Coxsackievirus, echoviruses, scabies, papular urticaria, dermatitis herpetiformis, folliculitis, parapsoriasis, and atypical measles can all cause widespread rashes.
• Rickettsialpox (also known as "herald spot" in serology) at the mite bite site.
MEDICATION FOR TREATMENT
First Phrase
• Within 24 hours of the disease's beginning, oral acyclovir is advised for varicella.
• Immunocompetent kids ≥2 years old and weighing ≤40 kg: taken orally in four dosages per day for five days at a maximum of 80 mg/kg/day.
• Adults or children above 40 kg: 3200 mg taken orally four times a day for five days.
• Patients must drink enough water.
• For seven days, apply a topical solution to each lesion six times a day.
Line Two
• Famciclovir (adults: 500 mg orally three times daily for seven days; not established for children under the age of eighteen) and valacyclovir (children 2–18 years: 20 mg/kg; adults: 1 g orally three times daily for seven days) are more effective against VZV and have superior absorption compared to acyclovir. There is little information on valacyclovir's ability to treat chickenpox.
• Although myelosuppression is a significant and frequent side effect, ganciclovir is also effective against VZV.
ADDITIONAL MEDICATION
Overall Actions
• Unless a problem arises or the patient is at high risk for problems (such as pregnant women or individuals with impaired immune systems), appropriate medical care is typically provided as an outpatient.
• Astringent soaks, cautious bathing, and closely clipped fingernails to avoid scratching are general precautions.
Oral antipruritic medications.
• Antibiotics applied topically to treat bacterial infections.
• For fever, take paracetamol or acetaminophen.
• Acetylsalicylic acid, or aspirin, increases the risk of developing Reye's syndrome.
Continuing Care Follow-Up Suggestions
Monitoring of Patients
In high-risk groups, keep an eye on respiratory function (% hemoglobin O2 saturation).
PATIENT EDUCATION • Following immunization, a person should avoid contact with a pregnant woman for three months and refrain from taking aspirin for six weeks.
• Getting vaccinated while pregnant is not advised. • Explain to the patient how contagious the illness is.
PROGNOSIS: The majority of instances are minor.
• The virus stays dormant in the sensory ganglia, and herpes zoster is caused by reactivation (secondary infection).
• Lifelong immunity is nearly always produced by varicella.
• Immunocompromised patients, adults, pregnant women, and their unborn child may be at risk for death.
DIFFICULTIES
• In the US, the average yearly death toll from 2003 to 2005 was 16.
• A secondary bacterial infection primarily caused by group A streptococci or staphylococci. The neutropenic host may develop a systemic infection as a result.
• Varicella pneumonia primarily affects immunocompromised patients and adults (1 in 400 cases). During the second or third trimester of pregnancy, it might be fatal. Tachypnea, cough, dyspnea, and fever are the symptoms that often appear three to five days after the sickness starts. An x-ray of the chest reveals interstitial or nodular pneumonitis. Even when there are no clinical symptoms, alterations on chest x-rays may be visible.
• Cerebellar ataxia can occur up to 21 days after the rash first appears, but generally within a week. It affects 1 in 4000 people and typically occurs in those under the age of 15. Ataxia, vertigo, fever, tremor, emesis, and dysphasia are among the symptoms. Examining the cerebrospinal fluid reveals increased protein and lymphocytosis. It usually goes away in two to four weeks and is a benign consequence.
• In the first week of illness, 0.1–0.2% of patients develop encephalitis, which can be fatal in adults. It manifests as a lower degree of
seizures, fever, changed cognitive processes, headache, vomiting, and consciousness. The mortality rate is between 5 and 20%, and 15% of survivors have neurologic sequelae. It lasts for at least two weeks.
• Transverse myelitis and meningitis; • Reye's syndrome, which manifests in the latter stages of the illness and has been epidemiologically linked to aspirin intake. In addition to myocarditis, nephritis, bleeding diathesis, and (rarely) hepatitis, it manifests as vomiting, restlessness, irritability, a progressive decline in consciousness, progressive cerebral edema, hyperammonemia, bleeding diathesis, hyperglycemia, and increased transaminases.
ESSENTIALS DESCRIPTION
A rash with concurrently present various stages of evolution (containing combinations of macules, papules, vesicles, and pustules) is the hallmark of chickenpox, a feverish, highly contagious illness that typically affects young children and is caused by a primary infection with the varicella zoster virus (VZV).
The study of epidemiology
The prevalence
• It is found all throughout the world and manifests as outbreaks in the late winter and early spring.
• 90% of vulnerable subjects experience a primary attack, and 70–90% of the same family experiences a secondary attack.
• Because of the immunization campaign, the incidence is declining (1). The frequency
• In two US towns where varicella is recorded, the incidence decreased by 90% between 1995 and 2005 as a result of vaccination (2).
• Moreover, related deaths, complications, expenses, and hospitalizations have decreased (2).
Males and females are the dominant sexes.
• Close contact between a nonimmune individual and a patient who is spreading the virus (exposure to varicella or herpes zoster) is a risk factor.
About 90% of occurrences occur in youngsters under the age of three. • Of people aged ≥15, 90% are immune, whereas 10% are still vulnerable.
• The number of instances in adulthood is rising.
OVERALL PREVENTION
Until the patient is no longer contagious, they must be kept out of school: Until all of the vesicles have crusted, a patient is contagious 48 hours before the rash appears (at the conclusion of the incubation period).
Immunization via Passive
• Varicella zoster immunoglobulin ought to be administered subsequent to
exposure to cases of herpes zoster or chickenpox in the following groups: susceptible pregnant women; susceptible immunocompetent adults and adolescents; and susceptible immunocompromised youngsters
- newborns born to mothers who contract chickenpox five days prior to or two days following delivery - Premature newborns admitted to hospitals (birth weight <1000 g, regardless of maternal history, or ≥28 weeks gestation when mother has no history chickenpox)< />pan>
• It should be injected intramuscularly within 96 hours, ideally within 72 hours, of exposure. Newborns receive 125U, while everyone else receives 125U/10 kg body weight (up to 625U).
Vaccination: Since 1995, the US has licensed the live attenuated VZV vaccine (Varivax: 0.5 mL s.c.) (1). In the United States, children older than 12 months are typically advised to receive two doses of this vaccination (3).
• Attenuated virus vaccination at ages 4–6 years and 12–15 months. With a minimum of three months between doses, the second dose may be given prior to age four (3).
• Children between the ages of 12 months and 12 years must wait at least 3 months between doses; however, if the gap is at least 28 days, the second dose may be accepted. For kids who are at least 13 years old, the minimum
There is a 28-day gap between dosages (3).
• It is recommended that adults without a history of chickenpox who have not received the vaccination receive it. Give two doses separated by at least 28 days if you have never been vaccinated, or the second dose if you have received just one dose (3).
• The VZV vaccine can also be given in combination with the measles, mumps, rubella, and varicella vaccines.
Pathophysiology
The respiratory mucous membranes allow the virus to enter the body, where it multiplies in local lymph nodes. Primary cell associated viremia is the means by which peripheral blood mononuclear cells become infected. The virus spreads to cutaneous epithelial cells by a secondary viremia. In ganglia, it stays dormant for life (4).
ETIOLOGY • Varicella zoster virus (HHV-3, DNA virus, genus: Varicellovirus, family: Herpesviridae).
• VZV does not have a recognized animal reservoir. The only reservoir is humans.
• Person-to-person contact is the means of transmission; the virus replicates in the nasopharynx or upper respiratory tract and is transmitted through the respiratory system and vesicle fluid.
respiratory system.
History of Diagnosis
• The duration of incubation is 10–14 days, with a range of 10–21 days.
• Affected systems include the skin, respiratory, central nervous system, disseminated/viremia, and other viscera.
Children who are immunocompetent may experience prodromal symptoms 1-2 days before the rash appears. low-grade fever and malaise.
• Constitutional symptoms include anorexia, pruritus, malaise, low-grade fever, and listlessness.
Rash.
Patients with weakened immune systems
• A greater number of hemorrhagic-based lesions.
• Three times longer healing time.
• More likely to experience visceral problems (30–50% of instances; 15% of those are deadly).
Adults
• A more serious condition. • A higher chance of visceral problems.
Women Who Are Expectant
more susceptible to congenital transmission to the fetus and maternal pneumonia (4).
Varicella in perinatal
• High mortality rate (30%) • Progressive disease involving viscera, especially the lung, and death in the infant may result from the mother contracting chickenpox 5 days prior to delivery and 48 hours following.
Varicella congenital
Severe deformities (skin scarring, hypoplastic extremities, anomalies of the eyes, and CNS dysfunction) can result from a teratogenic virus infection of the fetus during the first two trimesters of pregnancy.
MEDICAL EXAMINATION
• Rash: Spreads centripetally from the face and trunk. Mucous membranes may be affected, and
the vagina. Maculopapular at first, it transforms into vesicles that contain transparent fluid. After a few hours, the fluid becomes purulent. Lesions range in size from 5 to 13 mm in diameter, round or oval, and have an erythematous base. As the healing process advances, central umbilication emerges. The development of new lesions is followed and coexisted with by crust formation. Every type of lesion is simultaneously present at different phases of development. Lesions typically develop in subsequent crops over a period of two to four days.
• Within a week or two of commencement, the crusts break off, leaving a slightly depressed patch of skin that is scar-free unless it is superinfected.
Diagnostic Examinations and Interpretation Laboratory
Although the diagnosis is primarily clinical, it should be remembered that novice doctors have little knowledge of chickenpox (1).
PCR analysis of a clinical samples to detect VZV DNA (1, 5). The most dependable technique is PCR.
It takes roughly three days to isolate VZV from material extracted from the bottom of the lesions (viral culture).
Multinucleated giant cells are visible in a Tzanck smear taken from the bottom of a vesicle.
VZV detection in smears using direct
tests such as immunofluorescence staining (DFA).
• Serology: Convalescent serum samples with a fourfold or higher rise in IgG antibody (ELISA test) or seroconversion (positive IgM antibody). There may not be a fourfold rise in vaccinated subjects (5). Imagining
• Only 10% of individuals with positive chest x-rays experience clinical respiratory symptoms; 16% of chickenpox patients have abnormalities in their chest x-rays.
• Increased reticular shadowing or a nodular pattern are signs of pneumonitis.
DISTINCTIVE DIAGNOSIS
• Infection with the herpes simplex virus that spreads among atopic dermatitis patients.
Coxsackievirus, echoviruses, scabies, papular urticaria, dermatitis herpetiformis, folliculitis, parapsoriasis, and atypical measles can all cause widespread rashes.
• Rickettsialpox (also known as "herald spot" in serology) at the mite bite site.
MEDICATION FOR TREATMENT
First Phrase
• Within 24 hours of the disease's beginning, oral acyclovir is advised for varicella.
• Immunocompetent kids ≥2 years old and weighing ≤40 kg: taken orally in four dosages per day for five days at a maximum of 80 mg/kg/day.
• Adults or children above 40 kg: 3200 mg taken orally four times a day for five days.
• Patients must drink enough water.
• For seven days, apply a topical solution to each lesion six times a day.
Line Two
• Famciclovir (adults: 500 mg orally three times daily for seven days; not established for children under the age of eighteen) and valacyclovir (children 2–18 years: 20 mg/kg; adults: 1 g orally three times daily for seven days) are more effective against VZV and have superior absorption compared to acyclovir. There is little information on valacyclovir's ability to treat chickenpox.
• Although myelosuppression is a significant and frequent side effect, ganciclovir is also effective against VZV.
ADDITIONAL MEDICATION
Overall Actions
• Unless a problem arises or the patient is at high risk for problems (such as pregnant women or individuals with impaired immune systems), appropriate medical care is typically provided as an outpatient.
• Astringent soaks, cautious bathing, and closely clipped fingernails to avoid scratching are general precautions.
Oral antipruritic medications.
• Antibiotics applied topically to treat bacterial infections.
• For fever, take paracetamol or acetaminophen.
• Acetylsalicylic acid, or aspirin, increases the risk of developing Reye's syndrome.
Continuing Care Follow-Up Suggestions
Monitoring of Patients
In high-risk groups, keep an eye on respiratory function (% hemoglobin O2 saturation).
PATIENT EDUCATION • Following immunization, a person should avoid contact with a pregnant woman for three months and refrain from taking aspirin for six weeks.
• Getting vaccinated while pregnant is not advised. • Explain to the patient how contagious the illness is.
PROGNOSIS: The majority of instances are minor.
• The virus stays dormant in the sensory ganglia, and herpes zoster is caused by reactivation (secondary infection).
• Lifelong immunity is nearly always produced by varicella.
• Immunocompromised patients, adults, pregnant women, and their unborn child may be at risk for death.
DIFFICULTIES
• In the US, the average yearly death toll from 2003 to 2005 was 16.
• A secondary bacterial infection primarily caused by group A streptococci or staphylococci. The neutropenic host may develop a systemic infection as a result.
• Varicella pneumonia primarily affects immunocompromised patients and adults (1 in 400 cases). During the second or third trimester of pregnancy, it might be fatal. Tachypnea, cough, dyspnea, and fever are the symptoms that often appear three to five days after the sickness starts. An x-ray of the chest reveals interstitial or nodular pneumonitis. Even when there are no clinical symptoms, alterations on chest x-rays may be visible.
• Cerebellar ataxia can occur up to 21 days after the rash first appears, but generally within a week. It affects 1 in 4000 people and typically occurs in those under the age of 15. Ataxia, vertigo, fever, tremor, emesis, and dysphasia are among the symptoms. Examining the cerebrospinal fluid reveals increased protein and lymphocytosis. It usually goes away in two to four weeks and is a benign consequence.
• In the first week of illness, 0.1–0.2% of patients develop encephalitis, which can be fatal in adults. It manifests as a lower degree of
seizures, fever, changed cognitive processes, headache, vomiting, and consciousness. The mortality rate is between 5 and 20%, and 15% of survivors have neurologic sequelae. It lasts for at least two weeks.
• Transverse myelitis and meningitis; • Reye's syndrome, which manifests in the latter stages of the illness and has been epidemiologically linked to aspirin intake. In addition to myocarditis, nephritis, bleeding diathesis, and (rarely) hepatitis, it manifests as vomiting, restlessness, irritability, a progressive decline in consciousness, progressive cerebral edema, hyperammonemia, bleeding diathesis, hyperglycemia, and increased transaminases.
